
==== Front
PLoS Negl Trop Dis
PLoS Negl Trop Dis
plos
PLOS Neglected Tropical Diseases
1935-2727
1935-2735
Public Library of Science San Francisco, CA USA

39236081
10.1371/journal.pntd.0012477
PNTD-D-24-00341
Research Article
Biology and life sciences
Cell biology
Chromosome biology
Chromatin
Chromatin modification
DNA methylation
Biology and life sciences
Genetics
Epigenetics
Chromatin
Chromatin modification
DNA methylation
Biology and life sciences
Genetics
Gene expression
Chromatin
Chromatin modification
DNA methylation
Biology and life sciences
Genetics
DNA
DNA modification
DNA methylation
Biology and life sciences
Biochemistry
Nucleic acids
DNA
DNA modification
DNA methylation
Biology and life sciences
Genetics
Epigenetics
DNA modification
DNA methylation
Biology and life sciences
Genetics
Gene expression
DNA modification
DNA methylation
Biology and Life Sciences
Genetics
Epigenetics
Medicine and Health Sciences
Oncology
Cancer Treatment
Epigenetic Therapy
Biology and Life Sciences
Cell Biology
Signal Transduction
Cell Signaling
Signaling Cascades
WNT Signaling Cascade
Biology and Life Sciences
Genetics
Gene Types
Suppressor Genes
Tumor Suppressor Genes
Medicine and Health Sciences
Oncology
Cancers and Neoplasms
Medicine and Health Sciences
Oncology
Cancers and Neoplasms
Breast Tumors
Breast Cancer
Medicine and Health Sciences
Oncology
Cancers and Neoplasms
Carcinoma
Hepatocellular Carcinoma
Medicine and Health Sciences
Oncology
Cancers and Neoplasms
Gastrointestinal Tumors
Hepatocellular Carcinoma
Medicine and Health Sciences
Gastroenterology and Hepatology
Liver Diseases
Hepatocellular Carcinoma
Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities
Epigenetic Biomarkers associated with Ov-CCA and Therapeutic Opportunities
https://orcid.org/0000-0002-0048-5699
Kafle Alok Conceptualization Data curation Formal analysis Investigation Methodology Visualization Writing – original draft Writing – review & editing 1 2
https://orcid.org/0000-0002-2323-2344
Suttiprapa Sutas Conceptualization Funding acquisition Validation Visualization Writing – original draft Writing – review & editing 1 2 *
Muhammad Mubarak Data curation Formal analysis Methodology 3
Tenorio Jan Clyden B. Data curation Formal analysis Methodology 1 2
Mahato Roshan Kumar Formal analysis Methodology Writing – review & editing 4
https://orcid.org/0000-0003-1457-2758
Sahimin Norhidayu Funding acquisition Validation Writing – review & editing 5
https://orcid.org/0000-0001-7511-860X
Loong Shih Keng Funding acquisition Validation Writing – review & editing 5
1 Department of Tropical Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
2 WHO Collaborating Centre for Research and Control of Opisthorchiasis, Khon Kaen University, Khon Kaen, Thailand
3 Department of Physiology and Graduate School, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
4 Faculty of Public Health, Khon Kaen University, Khon Kaen, Thailand
5 Tropical Infectious Diseases Research & Education Centre, Universiti Malaya, Kuala Lumpur, Malaysia
Taylan Ozkan Aysegul Editor
TOBB Economics and Technology University Faculty of Medicine: TOBB Ekonomi ve Teknoloji Universitesi Tip Fakultesi, TÜRKIYE
The authors have declared that no competing interests exist.

* E-mail: sutasu@kku.ac.th
5 9 2024
9 2024
18 9 e00124777 3 2024
19 8 2024
© 2024 Kafle et al
2024
Kafle et al
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Background

Epigenetic modifications, such as DNA methylation and histone modifications, are pivotal in regulating gene expression pathways related to inflammation and cancer. While there is substantial research on epigenetic markers in cholangiocarcinoma (CCA), Opisthorchis viverrini-induced cholangiocarcinoma (Ov-CCA) is overlooked as a neglected tropical disease (NTD) with limited representation in the literature. Considering the distinct etiological agent, pathogenic mechanisms, and pathological manifestations, epigenetic research plays a pivotal role in uncovering markers and potential targets related to the cancer-promoting and morbidity-inducing liver fluke parasite prevalent in the Great Mekong Subregion (GMS). Emerging studies highlight a predominant hypermethylation phenotype in Opisthorchis viverrini (O. viverrini) tumor tissues, underscoring the significance of abnormal DNA methylation and histone modifications in genes and their promoters as reliable targets for Ov-CCA.

Principal findings

Relevant published literature was identified by searching major electronic databases using targeted search queries. This process retrieved a total of 81 peer-reviewed research articles deemed eligible for inclusion, as they partially or fully met the pre-defined selection criteria. These eligible articles underwent a qualitative synthesis and were included in the scoping review. Within these, 11 studies specifically explored Ov-CCA tissues to investigate potential epigenetic biomarkers and therapeutic targets. This subset of 11 articles provided a foundation for exploring the applications of epigenetics-based therapies and biomarkers for Ov-CCA. These articles delved into various epigenetic modifications, including DNA methylation and histone modifications, and examined genes with aberrant epigenetic changes linked to deregulated signalling pathways in Ov-CCA progression.

Conclusions

This review identified epigenetic changes and Wnt/β-catenin pathway deregulation as key drivers in Ov-CCA pathogenesis. Promoter hypermethylation of specific genes suggests potential diagnostic biomarkers and dysregulation of Wnt/β-catenin-modulating genes contributes to pathway activation in Ov-CCA progression. Reversible epigenetic changes offer opportunities for dynamic disease monitoring and targeted interventions. Therefore, this study underscores the importance of these epigenetic modifications in Ov-CCA development, suggesting novel therapeutic targets within disrupted signalling networks. However, additional validation is crucial for translating these novel insights into clinically applicable strategies, enhancing personalised Ov-CCA management approaches.

Author summary

This review examines the role of epigenetic changes and the Wnt/β-catenin signalling pathway in Opisthorchis viverrini-induced cholangiocarcinoma (Ov-CCA). Through an exhaustive analysis of relevant studies, the primary epigenetic alteration identified in Ov-CCA pathogenesis is hypermethylation of tumor suppressor gene promoters. This epigenetic dysregulation shows several affected genes involved in the Wnt/β-catenin signalling pathway, which plays a central role in opisthorchiasis progression. Network analysis revealed an interaction between these genes and β-catenin, suggesting Wnt/β-catenin pathway dysregulation contributes to Ov-CCA development and progression. Most methylated genes act as tumor suppressors by normally inhibiting the Wnt/β-catenin pathway. Targeting this pathway offers therapeutic potential for Ov-CCA. Epigenetic markers hold promise as biomarkers, emphasizing the therapeutic potential of targeting disrupted gene and signalling networks through epigenetic modulators. This approach presents an innovative strategy for developing personalized therapies tailored to the molecular profiles of Ov-CCA patients. However, translating these findings into clinical practice requires rigorous validation and further in-depth exploration. Nonetheless, the insights obtained highlight the crucial necessity for ongoing research on epigenetic-based interventions, intending to enhance both diagnostic accuracy and therapeutic effectiveness in managing Ov-CCA.

The Ministry of Higher Education, Malaysia under Dana Langganan SUKUK Pakej Rangsangan Ekonomi Prihatin Rakyat (SUKUK PRIHATIN)-Fasa 2 MO002-2021 https://orcid.org/0000-0001-7511-860X
Loong Shih Keng Postgraduate Scholarships for International Students (PGIS), Faculty of Medicine, Khon Kaen University https://orcid.org/0000-0002-0048-5699
Kafle Alok NS and SKL received fundings from the Ministry of Higher Education, Malaysia under Dana Langganan SUKUK Pakej Rangsangan Ekonomi Prihatin Rakyat (SUKUK PRIHATIN)-Fasa 2 (MO002-2021). AK is supported by the Postgraduate Scholarships for International Students (PGIS), Faculty of Medicine, Khon Kaen University. SS was supported by the Fundamental Fund of Khon Kaen University and the National Science, Research, and Innovation Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. PLOS Publication Stagevor-update-to-uncorrected-proof
Publication Update2024-09-17
Data AvailabilityThe data supporting the findings of this study are available within the manuscript and its supplementary materials.
Data Availability

The data supporting the findings of this study are available within the manuscript and its supplementary materials.
==== Body
pmc1 Introduction

Liver fluke infections caused by parasites like Clonorchis sinensis, Opisthorchis felineus, and Opisthorchis viverrini (O. viverrini) are significant public health challenges prevalent in Eastern Europe, East Asia, and Southeast Asia [1]. O. viverrini infections are particularly endemic in Southeast Asian nations, including Thailand, Lao PDR, Cambodia, and Vietnam [2]. The association between liver fluke infestation and cholangiocarcinoma (CCA) is well documented. The International Agency for Research on Cancer (IARC) has classified O. viverrini and C. sinensis as Group I agents, recognising them as biological carcinogens [3].

Approximately 10 million individuals in the Great Mekong Subregion (GMS) are believed to be infected with O. viverrini. Over 6 million Thai residents are affected by O. viverrini, with the most significant prevalence in Northeastern Thailand [4]. Liver and bile duct cancer is also one of the top ten diseases associated with high mortality within the Thai population [5]. The elevated occurrence of this concerning issue is intricately linked to the widespread existence of the liver fluke parasite, O. viverrini, thereby substantially heightening the susceptibility to CCA. Unfortunately, many patients in this region are diagnosed with advanced-stage CCA, resulting in an exceptionally high mortality rate [6]. Epigenetic alterations can help provide pivotal insights for early marker discovery, identify altered signalling pathways, and provide alternatives to exploring therapeutic targets.

Over the last twenty years, there has been a recognition of the critical role played by epigenetic mechanisms as key regulators capable of initiating and sustaining cholangiocarcinogenesis [7,8]. However, the understanding of the molecular genetics and epigenetic mechanisms in Opisthorchis viverrini-induced cholangiocarcinoma (Ov-CCA) is limited compared to non-Opisthorchis viverrini-induced cholangiocarcinoma (non-Ov-CCA). Exome sequencing revealed evident differences in mutational patterns between Ov-CCA and non-Ov-CCA [9]. Early cancer detection is crucial, and epigenetic therapy can prevent malignant progression. More importantly, within Ov-CCA, discernible inter-tumor epigenetic heterogeneity offers the potential for tailoring personalised therapy approaches based on methylation or histone modifications [7].

This epigenetic modification hinders transcription of the methylated DNA, ultimately causing gene silencing in Ov-CCA tissues [10]. Although we do not delve into demethylating drugs, palliative chemotherapy, current natural and bioactive compounds, and epigenetic inhibitors involved in ongoing CCA clinical trials (given their absence for Ov-CCA), this review holds the potential to propel advancements in infection prognosis, target markers, and therapeutic monitoring for Ov-CCA. Hence, this scoping review consolidates recent research findings primarily centered on epigenetic markers and their significance in early detection, prognosis assessment, and potential implicated pathways. These insights offer valuable groundwork for future studies centered on epigenetics in the context of liver fluke-induced CCA.

1.1 Rationale

The prognosis for both Ov-CCA and non-Ov-CCA is poor, given their low resection rate and resistance to traditional radiotherapy and chemotherapy [11]. Subsequent research endeavours in Ov-CCA and epigenetics have illuminated a recurring theme. Although abnormal promoter hypermethylation is pervasive in tumor development, the specific genes affected exhibit similarity to the distinctive biology of Opisthorchiasis-induced cancer; however, results may vary according to the gender, age, and grade of an individual patient.

Methylation changes disrupt cell signalling pathways, and it’s possible to identify and narrow down affected genes and promoters by focusing on conserved pathways. Until now, there has been no scoping or systematic review of current literature on the role of epigenetic modification in Ov-CCA studies. Therefore, we aim to identify and synthesise all available epigenetic evidence through a scoping review. Exploring the broader landscape of this topic will yield more options than concluding limited evidence, aligning with the scoping review’s ability to map critical concepts, inquire about types of evidence, and identify gaps across a diverse evidence base. This approach offers an overview of the current state and span of research activity. Furthermore, the results underscore the potential for shared mechanisms in Ov-CCA management, emphasising the promise of utilising epigenetic mediators for biomarker discovery, enhancing early detection, and advancing drug development for personalised and combined therapies.

1.2. Objectives

To determine key genes and proteins that exhibit altered epigenetic regulation during opisthorchiasis and Ov-CCA development.

To elucidate the key cellular signalling pathways affected by abnormal epigenetic alterations in Ov-CCA development and assess the potential of dysregulated epigenetic markers as diagnostic biomarkers or therapeutic targets.

To understand the current state of the science regarding epigenetic complications and alterations following Ov-CCA and highlight knowledge gaps in the literature to inform future research priorities in this field.

2. Methods

2.1 Eligibility criteria

This scoping review thoroughly examines studies on individuals diagnosed with Ov-CCA and positive tissue sections. The studies exclusively conducted in cell lines, animal studies, review articles, letters, case reports, or without any epigenetic component were excluded from this review. Only articles published in English were selected. The PCC (Population/Concept/Context) framework is employed to structure key concepts, focusing on the crucial involvement of DNA methylation and histone modifications in Ov-CCA pathogenesis (S1 Table). The exploration extends to identifying epigenetically regulated genes and pathways linked to opisthorchiasis-induced cancer. This nuanced approach contributes to the overall depth and precision of the scoping review and helps identify key characteristics or factors related to a concept.

2.2 Search strategy

The methodology for this study was based on the guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR). A comprehensive search was conducted across five electronic databases: PubMed, SCOPUS, Science Direct, and the Cochrane Library. The scoping review presents an overview of a potentially large and diverse body of literature on a broad topic. Therefore, search queries were tailored to encompass the broader context of CCA and its associated epigenetic mechanisms: Epigenetics OR Epigenome* AND Bile duct cancer* OR cholangiocarcinoma. Initially, the search included studies on overall CCA, and subsequently, it was refined to focus on Ov-CCA studies that utilised human or human biopsy samples. The last search was done on August 30, 2023.

2.3 Data collection

The primary reviewer (AK), with the assistance of MM, conducted the literature search and compilation process. Any disparities in determining the inclusivity of the articles were deliberated upon, and final decisions were reached in consultation with subject matter experts, RKM, SKL, NS, and SS, who possess the requisite knowledge and expertise in tropical medicine and health science. Subsequently, all citations were imported into the desktop reference management application Endnote Reference Manager. Initially, duplicate citations were manually identified and eliminated, along with any duplicates discovered later in the process. Each citation’s title, abstract, and keywords were carefully assessed for relevance to the study before being exported into an Excel file along with the corresponding citation records. Any justifications for omitting citations were duly documented. Complete versions of articles that met the inclusion criteria were procured for further examination. The Excel data extraction form comprehensively recorded the following details: Author (Year), Population, Epigenetic hallmarks, Type of study, Outcome, Method used to measure Outcome, and Summary of the findings.

3. Results

In this review, we incorporated all studies investigating epigenetic mechanisms in the context of O. viverrini-related CCA. The initial search yielded 1050 records from the four electronic databases. After applying filters specific to each database, duplicates and non-research articles or those not in English were excluded, resulting in 337 remaining records. These were screened based on relevance indicated by their title, abstract, and keywords related to CCA. Additionally, duplicates between databases were removed. Of these, 256 records did not meet the inclusion criteria. Subsequently, 81 records underwent full-text retrieval. The remaining excluded records consist of 12 cell line studies, 49 non-Ov-CCA-based studies, 4 non-epigenetic studies, 2 irrelevant studies, 1 report, 1 review, and 1 study on an unrelated topic. Among these, 11 articles were ultimately included in this review, as they utilised human samples and pertained to the causation of Ov-CCA (Fig 1). Further confirmation of the use of human-infected Ov-CCA tissues was done by sending an e-mail to the corresponding authors of the included studies, as our contextual focus centers on human observational studies conducted in Ov-endemic regions within Southeast Asia and tissue samples collected across diverse stages of disease progression.

10.1371/journal.pntd.0012477.g001 Fig 1 Flowchart depicting the identification and selection process of studies.

3.1 Sample size and techniques

In the analysis, a total of 860 clinical samples from patients with Ov-CCA who tested positive for fluke infection were included from 11 selected studies. It’s noteworthy that most of these samples were paraffin-embedded specimens. The core methodologies frequently applied in Ov-CCA methylation studies using these clinical samples include PCR-based techniques, bisulfite sequencing, microarray screening, immunohistochemistry (IHC), quantitative PCR (qPCR), and comprehensive computational analysis (S2 Table). None of the studies conducted interventions involving human subjects.

3.2 Main findings

In our review, two principal epigenetic mechanisms—DNA methylation and histone modifications—have been identified, with DNA methylation predominantly featured in Ov-CCA-based epigenetic research. In our selection of 11 studies focused on Ov-CCA and epigenetic aspects, ten studies primarily investigated methylation patterns, with one study based on histone modifications (Table 1).

10.1371/journal.pntd.0012477.t001 Table 1 Summary of the findings from 11 included studies.

Author (Year)	Population	Epigenetic hallmarks	Type of study	Outcome	Method used to measure Outcome	Summary of the findings	Country	
Apinya Jusakul (2017)
[63]	Cases: 489 tumors ((133 Fluke-Pos: 132 O. viverrini, 1 C. sinensis; 39
HBV/HCV-positive; 5 PSC-positive, 312 CCAs of unspecified etiology)	Hypermethylation of CpG islands and CpG island shores	Non-randomized	Cluster 1 and 4 with hypermethylation of CpG islands and CpG island Shore respectively	Multiple omics techniques were used including whole genome sequencing, exome sequencing, targeted sequencing, copy number profiling, DNA methylation profiling and gene expression profiling	The study identified two distinct hypermethylated CCA subgroups: Cluster 1 with CpG island hypermethylation potentially driven by TET1 and EZH2 dysregulation, and Cluster 4 with CpG shore hypermethylation likely due to IDH1/2 mutations. Additionally, Cluster 1 tumors showed a correlation between hypermethylated regions and Signature 1 mutations, indicating disparate somatic evolution between the clusters. Understanding the molecular characteristics of CCA subtypes can lay the groundwork for future research into diagnostic biomarkers and personalized treatment approaches.	Thailand	
Prasong Khaenam (2009)
[17]	81 CCA tumor tissue samples from patients undergoing surgery,
69 matched non-tumor liver tissue samples	Promoter Methylation (RIZ1)	Non-randomized (retrospective study)	promoter methylation status of RIZ1 and the presence of LOH (loss of heterozygosity) and frameshift mutations in RIZ1	Methylation-specific PCR, PCR and fragment analysis, and statistical analysis between RIZ1 alterations and patient data.	RIZ1 promoter methylation is common in CCA tumors, and LOH at RIZPro704 is associated with poor patient survival, possibly through the disruption of RIZ1’s interaction with estrogen receptor. These alterations could serve as potential biomarkers for prognosis and suggest therapeutic strategies targeting RIZ1 expression	Thailand	
Temduang Limpaiboon (2004)
[15]	65 intrahepatic cholangiocarcinoma tumor samples
No control/normal samples	Promoter methylation of hMLH1 gene	Cross-sectional	hMLH1 promoter methylation status
Loss of heterozygosity (LOH) and microsatellite instability (MSI) at hMLH1 locus	Methylation specific PCR (MSP) to detect hMLH1 promoter methylation
Microsatellite marker analysis to detect LOH and MSI	hMLH1 was frequently methylated in CCA, suggesting epigenetic inactivation is a major mechanism leading to mismatch repair deficiency. hMLH1 methylation status shows potential as a CCA biomarker for diagnostic or prognosis.	Thailand	
Chaiyachet Nanok (2018)
[20]	54 cholangiocarcinoma (CCA) tissue samples, 19 matched adjacent normal tissue samples	DNA methylation levels of 10 candidate genes involved in various cellular processes PPP4C (DNA repair)
RUNX3, IRF4, UCHL1, TP53I3 (apoptosis)
CCND2, RASSF1 (cell proliferation)
ALDH1A3, SLC29A1 (drug metabolism)
HTATIP2 (angiogenesis)	Cross-sectional	DNA methylation levels of the genes HTATIP2 and UCHL1 correlated with overall patient survival	Methylation-sensitive high-resolution melting (MS-HRM) 10 candidate genes involved in DNA repair, apoptosis, cell proliferation, drug metabolism, and angiogenesis)	High HTATIP2 and low UCHL1 methylation correlated with longer survival in CCA patients. Both genes showed higher methylation in CCA tumors than adjacent normal tissues. HTATIP2 and UCHL1 methylation status may be predictive biomarkers for CCA prognosis, with potential therapeutic implications	Thailand	
Wiphawan Wasenang (2019)
[21]	40 CCA patients, 40 patients with other biliary diseases (control group)	DNA methylation of OPCML, HOXA9, and HOXD9	Cross-sectional	Methylation levels of OPCML, HOXA9, and HOXD9 in serum cell-free DNA	Methylation-sensitive high-resolution melting (MS-HRM) to quantify methylation levels	Serum methylation levels of OPCML and HOXD9 differ significantly between CCA and controls. OPCML’s methylation has high accuracy (AUC 0.850) for CCA diagnosis. Combined OPCML and HOXD9 methylation yields 100% specificity and PPV. Both markers show potential as non-invasive CCA differentiators	Thailand	
Kanlayanee Sawanyawisuth (2016)
[16]	85 cholangiocarcinoma (CCA) tissue samples, 15 matched pairs of normal and CCA tissues for methylation analysis, 6 CCA cell lines	DNA methylation status of the TROP2 gene promoter	Non-randomized	Expression levels and functions of TROP2 in liver fluke associated CCA	Immunohistochemistry (IHC),
Bisulfite Genomic Sequencing (BGS),
siRNA Knockdown,
Cell Proliferation Assay,
Migration and Invasion Assays,.
Real-time PCR,
PCR Array,
Western Blotting.	TROP2 exhibited reduced expression in CCA tissues, accompanied by promoter hypermethylation in 60% of cases; its knockdown promoted proliferation and migration of CCA cells, possibly through modulation of genes like MARCKS, EMP1, and FILIP1L, implicating TROP2 in the regulation of proliferation and migration. TROP2 could serve as a potential epigenetic biomarker (diagnostic) or therapeutic target (claimed from cell line based study) in liver fluke-associated cholangiocarcinoma (CCA)	Thailand	
Ruethairat Sriraksa (2014)
[66]	28 primary intrahepatic CCA samples, 6 matched adjacent normal tissue samples
Additional 102 CCA and 24 normal samples for validation	DNA methylation	Non-randomized	Genome-wide DNA methylation profiles
Methylation levels of specific genes (e.g. HOX genes)	Illumina Infinium HumanMethylation27 BeadChips,
Bisulfite pyrosequencing,
Bioinformatic analyses of methylation data	The study found 1610 differentially methylated CpG sites in CCA compared to normal tissues: 809 CpG sites were hypermethylated (603 genes) and 801 were hypomethylated (712 genes). Notably, hypermethylation was enriched at homeobox and PRC2 target genes, including HOXA9 and HOXD9, revealing a stem cell-like pattern. These findings propose HOXA9 genes as potential biomarkers and epigenetic therapies for CCA.	Thailand	
Ruethairat Sriraksa (2011) [8]	102 primary liver fluke-related cholangiocarcinoma (CCA) samples, 29 adjacent normal tissue samples.
Paraffin-embedded sections of CCA samples for immunohistochemistry.	DNA methylation	Non-randomized	Methylation frequency of 26 genes
Association with clinicopathological features	MSP, pyrosequencing, COBRA, immunohistochemistry	High methylation frequency of OPCML, SFRP1, HIC1, PTEN, and DcR1 in CCA compared to normal tissue. OPCML methylation is linked to less differentiated CCA, while DcR1 methylation is tied to longer survival. Study shows common promoter hypermethylation in CCA, suggesting OPCML and DcR1 as potential biomarkers for prognosis and treatment response.	Thailand	
Patcharee Chinnasri (2009)
[19]	94 ICCA patients (63 men, 31 women; median age 54)	DNA methylation of p14ARF, p15INK4b and p16INK4a (tumor suppressor genes (TSGs) located on chromosome 9p21)	Non-randomized, observational study on human samples	LOH and MSI at 9p21-pter
Methylation frequency
Protein expression by immunohistochemistry	Microdissection, PCR, methylation-specific PCR, immunohistochemistry	Liver fluke–related CCA shows high LOH at 9p21-pter, affecting p14ARF, p15INK4b, and p16INK4a genes. Aberrant methylation leads to their reduced expression. LOH and methylation link to p14ARF loss. p16INK4a loss might predict poor prognosis. DNA methylation of these genes could be diagnostic biomarkers. These genes are potential therapeutic targets for liver fluke related CCA due to their role in disease progression	Thailand	
Wiphawan Wasenang (2019)
[99]	40 cholangiocarcinoma (CCA) cases
Adjacent [38] non-cancerous tissue from the same patients acted as controls	Histone H3 lysine 27 (H3K27) trimethylation by PRC2 complex	Non-randomized	Measurement of EZH2, SUZ12, EED expression	Immunohistochemistry
Semi-quantitative scoring (H-score)
Kaplan-Meier survival analysis	
EZH2 and SUZ12 are highly expressed in CCA compared to adjacent tissue. High EZH2 links to worse survival; combined high EZH2, SUZ12, and EED associated with poorer prognosis, proposing EZH2 as a CCA prognostic biomarker. PRC2 overexpression suggests epigenetic inhibitors for therapy.	Thailand	
Napat Armartmuntree (2021)
[18]	138 CCA tumor tissues, and 4 normal bile duct tissues	DNA methylation patterns of EBF1 gene promoter region	Non-randomized	EBF1 promoter methylation and expression analyses in patient samples	Methylation-specific PCR on 72 CCA tissues, DNA methylation array data (Illumina 450K)	Targeting EBF1 promoter hypermethylation throC5:J21ugh DNMT inhibition may offer a promising epigenetic therapy for cholangiocarcinoma (CCA) with potential prognostic value as a biomarker, by restoring EBF1 expression and acting as a tumor suppressor to improve outcomes.	Thailand	

Additionally, our analysis identified the Wnt/β-catenin pathways as the most prominently affected, both directly and indirectly, in the context of epigenetically dysregulated genes associated with Ov-CCA (Table 2). A more comprehensive understanding of recent updates on inhibitors, antagonists, and activators of the Wnt/β-catenin pathway holds promise as a therapeutic approach, given its prominence in O. viverrini related epigenetic research.

10.1371/journal.pntd.0012477.t002 Table 2 Epigenetic alterations in studied genes/proteins and their impact on critical gene pathways in Ov-CCA.

Epigenetic Change	Possible major pathways affected	
RIZ1 promoter methylation [17]	-Cell cycle regulation AKT/mTOR [175], IGF-1 (insulin-like growth factor 1) [17,176] and estrogen receptor signalling [46]	
EBF1 promoter methylation [18]	- B cell development, differentiation, and immune function–HIF1-alpha pathway [177], suppressions of Wnt signalling pathway [18], Potentially PI3K/AKT and other oncogenic signalling [178]	
hMLH1 methylation [15]	- DNA mismatch repair capability—Microsatellite instability—Potential impact on MAPK, TGFβ, and other tumor-promoting pathways	
HTATIP2 and UCHL1 methylation [20]	- Angiogenesis signalling through VEGF, HIF1α, etc. [179]—Ubiquitination and protein turnover, association of UCHL1 with β-catenin signalling pathway [180]. UCHL1 could activate the p14ARF-p53 signalling pathway by deubiquitinating p53 and p14ARF [181]	
OPCML, HOXA9, HOXD9 methylation [21]	OPCML: Wnt signalling inhibitor and functions as tumour suppressor, Wnt/β-catenin and TGF-β-Smad pathways [139], HOX genes: β-catenin/Wnt pathway [182], (AXL)/STAT3 signalling pathways and embryonic development and cell differentiation [68,183,184], [182], HOXD9 [185].	
Trop2 methylation [16]	Calcium signalling [186], cell proliferation, and survival—WNT, SRC, AKT, and ERK/MAPK pathways [187] regulating migration extracellular signal-regulated kinase (ERK) [16].	
EZH2 overexpression [99]	-Estrogen signalling pathways [133], Aberrant epigenetic repression of tumour suppressors via PRC2 [99], increase the expression of multiple Wnt pathway genes [98]	

3.2.1 DNA Methylation and Histone Modifications: Focusing on Biomarkers and Therapeutic Targets

DNA methylation and histone modifications exhibit remarkable potential as biomarkers for early detection, diagnosis, prognosis, and therapeutic monitoring in cancer [12,13]. In Ov-CCA tissues, epigenetic modification hinders transcription of the methylated DNA, causing gene silencing and influencing the broader regulatory landscape of cellular processes [10]. DNA methylation markers are detectable in bodily fluids and offer non-invasive approaches to detect cancer onset and recurrence sensitively [14].

Epigenetic studies in Ov-CCA have demonstrated abnormalities in DNA methylation with promoter hypermethylation observed in several genes, hMLH1 [15], Trop2 [16], RIZ1 [17], EBF1 [18], p14A2RF, p15INK4B, p16INK4A [19], PPP4C (DNA repair), RUNX3, IRF4, UCHL1, TP53I3 (apoptosis), CCND2, RASSF1 (cell proliferation), ALDH1A3, SLC29A1 (drug metabolism), HTATIP2 (angiogenesis) [20], OPCML, SFRP1, HIC1, PTEN, and DcR1 [8], OPCML [21]. At the same time, UCHL1 was the only gene found to be hypomethylated in Ov-CCA [20].

A detailed analysis of the impact of the aforementioned specific genes on cancer development is presented below, emphasising their potential as markers for disease progression and therapeutic targets. It also highlights their potential as markers in disease progression and therapeutic targets. It further explores their direct or indirect involvement in the Wnt signalling pathways within the Ov-CCA pathology and progression context.

hMLH1 (human MutL homolog 1)

The acquisition of genomic instability stands as a pivotal hallmark of cancer cells, with hypermutable phenotypes known as microsatellite instability (MSI) and mismatch repair (MMR) representing a significant component of this phenomenon [22,23]. Methylation of the hMLH1 gene promoter region can lead to the silencing of hMLH1 expression, resulting in microsatellite instability (MSI) due to dysfunction of the MMR system [24–26]. MMR is crucial for precise genome replication during cell division. Deficiencies in this process can cause mutation rates up to 100 times higher than in normal cells [22,27].

The study by Limpaiboon et al. (2005) examined the loss of heterozygosity (LOH) and microsatellite instability (MSI) at the hMLH1 locus and reported hypermethylation in 44.6% of the liver in Ov-CCA cases [15]. There had been a research gap in determining the status of O. viverrini infection and MMR proteins. A recent study identified a 22.5% prevalence of dMMR in Ov-CCA patients [28]. While the study found no statistically significant association between OV IgG status and dMMR protein expression, further research is needed to explore the underlying mechanisms linking dMMR with improved survival and response to therapy. MSI is also an epiphenomenon of dMMR [29], as MSI often results from dMMR. Hence, an in-depth analysis should be considered in Ov-CCA tumor types to recognise the beneficial impact of dMMR and MSI in enhancing treatment effectiveness and potential as targets for therapeutic interventions.

Trophoblast cell surface antigen 2 (Trop2)

The protein Trop2 is produced by the TACSTD2 (Tumor-associated calcium signal transducer) gene [30]. Hypermethylation of the TACSTD2 gene, which encodes Trop2, can silence its expression, contributing to its downregulation in some cancer types [31]. Trop2 affects cancer cell apoptosis by upregulating Bcl2 and downregulating the expression of the pro-apoptotic protein Bax [32]. The Bax/Bcl-2 expression ratio is a critical determinant in cellular response to apoptotic stimuli. An increased ratio reduces resistance to apoptosis, leading to heightened cell death and a decreased tumor incidence [33].

In O. viverrini infection, Bax levels increase at 14 dpi (days post-infection) and decrease at 90 dpi. These fluctuations are associated with the host immune response and the repercussions of recurrent tissue repairs resulting from parasitic infection [34]. The downregulation and internalisation of Bax are associated with metastasis and recurrence [35,36]. Furthermore, during O. viverrini infection, NF-κB, generally upregulated [37], and upregulated NF-κB, is known to decrease Bax expression in cancer cell lines [38]. This finding bolsters the evidence showing Trop2 distinct epigenetic silencing in Ov-CCA [16]. Reduced Trop2 expression, caused by hypermethylation, could shift the Bax/Bcl-2 ratio, favouring a pro-apoptotic environment. Hence, Trop2, despite its usual overexpression in cancers, is epigenetically methylated and silenced in Ov-CCA, making it a unique prognostic marker for O. viverrini infection. It also opens up for the treatment enhancing Trop2 antibody-drug conjugates (ADCs) effectiveness through demethylating agents and transcription factor modulation for low Trop2 expression cancers, offering a novel therapeutic strategy [39].

Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1)

The RIZ1 gene has been accurately located on chromosome 1q36, a region prone to genetic alterations like deletions, rearrangements, and LOH in many types of human cancers [40–42]. Loss of RIZ1, a methyltransferase targeting lysine nine on histone H3, has been frequently observed in lung, breast, hepatocellular, colon, neuroblastoma, and melanoma, suggesting its potential role as a tumor suppressor in these malignancies [43].

In the case of Ov-CCA, Khaenam et al. (2010) showed that RIZ1 hypermethylation may play a potential role in cholangiocarcinogenesis, and the occurrence of RIZPro704 LOH is linked to poor patient survival in Ov-CCA [17]. RIZ1 hypermethylation may dysregulate ERα signalling and drive cancer progression [44, 45]. Compelling research evidence shows the correlation between reduced levels of RIZ1 and dysregulated ERα signalling in cancers [46,47]. Furthermore, higher levels of ER expression (specifically ERα) in cancer cells can lead to increased responsiveness to estrogen and potentially contribute to tumor progression [48,49]. In Ov-CCA, male patients exhibited markedly elevated serum estrogen levels compared to controls [50]. This suggests that the combined effects of opisthorchiasis and elevated estrogen levels may exhibit a complex impact on the tumor microenvironment, potentially promoting CCA development and progression.

Using siRNA to downregulate RIZ1 expression showed a correlation between diminished RIZ1 expression and heightened cell proliferation and migration in Ov-CCA [51]. The observed inverse epigenetic association with Ov-CCA differentiation underscores the potential of RIZ1 expression as a valuable indicator of its stage, aggressiveness, and differentiation.

EBF1 (Early B-cell Factor 1) in Ov-CCA

DNA hypermethylation within the EBF1 promoter region inhibits EBF1 expression and drives the progression of Ov-CCA, resulting in severe clinical outcomes [18]. EBF1 is a tumor suppressor in breast cancer [52], leukemia [53], and colorectal cancer [54] and inhibits gastric cancer progression by repressing the telomerase catalytic subunit [55].

Hypermethylation in the EBF1 promoter region correlates with reduced patient survival, repressing its expression and accelerating aggressive CCA advancement [56]. An inverse relationship between EBF1 expression and ZNF423 (Zinc Finger Protein 423) levels in tumor tissues leads to unfavourable prognostic outcomes [57]. In CCA, reduced ZNF423 leads to downregulated MMP9 expression and decreased EMT markers such as N-cadherin and vimentin [58]. Furthermore, ZNF423 is shown to have a complex relationship with EBF1 and can affect gene regulation in B-cell lymphopoiesis, including the downregulation of critical EBF1 targets and potential interference with TGF-β1 signalling [59].

The ability to manipulate EBF1 and ZNF423 levels can influence the disease’s course. The intricate relationship between these genes and their impact on the behaviour of the CCA cells strengthens the indication of their potential significance in both diagnosis and targeted treatment.

TP53 Mutations and ERBB2 Amplification in Ov-CCA

TP53 refers to the gene itself, while p53 denotes the protein produced by that gene. Specific missense p53 mutants actively alter the p53 interactome, influencing cellular pathways that promote cancer proliferation, migration, and metastasis [60]. Kiba et al. (1993) found p53 mutation in 35% of Thai CCA cases and suggested that p53 mutation is common in liver fluke related CCA [61]. In Ov-CCA tissues, immunohistochemistry analysis revealed an increase in p53 protein levels in 77% of the cases [62].

In a 2017 study, extensive DNA methylation analysis was conducted to investigate the link between multi-omics features and the aetiology of liver diseases [63]. Clusters 1 and 2, linked to liver fluke infection, exhibit common TP53 mutations and amplification of HER2 (ERBB2) in Ov-CCA. However, they diverge in CpG island hypermethylation, notably in cluster 1, underscoring the molecular heterogeneity of liver diseases with specific origins.

The HER2 receptor is a 185 kDa transmembrane protein encoded by the HER2, highlighting the importance of targeted therapies. A subset of Ov-CCA tissues display protein overexpression of HER2 [64] and exhibit ERBB2 gene amplification. Therefore, examining the impact of HER2 on various Ov-CCA subtypes could offer insights and raise the prospect that infected patients might gain advantages from rapidly evolving anti-HER2-directed therapies. These therapies emphasize personalised approaches, novel agents, and combinations to enhance efficacy while minimising side effects [65].

HOXD9 and OPCML in Epigenetic therapies and prognosis across cancer types

A study found that hypermethylation was enriched at homeobox and Polycomb Repressive Complex 2 (PCR2) target genes, including homeobox (HOXA9 and HOXD9) [66]. As HOXD9 deregulates histone methylation by PRC2 in cholangiocarcinogenesis, using histone methyltransferase inhibitors to block PCR2 and reactivate silenced HOX genes like HOXD9 could represent a potential epigenetic therapy approach for Ov-CCA. Therefore, understanding the specific methylation patterns and their consequences on HOX genes in Ov-CCA may provide a vital target for therapeutic interventions.

Opioid-binding protein/cell adhesion molecule-like gene (OPCML), an oncogenic suppressor, is frequently silenced by promoter hypermethylation [67]. In 2011, an initial report on OPCML methylation in Ov-CCA revealed a notably high frequency of 72.5%, while no methylation was detected in the adjacent normal tissues [8]. On the contrary, overexpression of OPCML can potentially suppress proliferation and induce apoptosis by deactivating the AXL receptor tyrosine kinase (AXL)/STAT3 signalling pathway in CCA [68]. This demonstrates a robust discriminatory capability of the gene, potentially effective in distinguishing Ov-CCA cancer cases from benign biliary conditions. Additionally, combining OPCML and HOXD9 methylation levels in cfDNA from serum samples provides a less invasive and more effective method for diagnosing and monitoring CCA [21].

Ubiquitin C-terminal hydrolase L1 (UCHL1)

UCHL1, a member of the UCH class of deubiquitinases (DUBs), has highlighted the importance of promoter region hypermethylation as a mechanism for gene inactivation in cancer [69,70]. UCHL1 is upregulated in Ov-CCA tissue samples and may be linked to hypomethylation in the promoter region and potential induction of UCHL1 expression through cancer-induced DNA repair mechanisms. [20]. High levels of HTATIP2 methylation, also known as CC3 or TIP30, is a gene that encodes a protein involved in various cellular processes. Low levels of UCHL1 methylation were found with extended overall survival in Ov-CCA [20]. Similarly, in gallbladder and breast cancer, UCHL1 exhibits overexpression due to promoter hypomethylation and correlates with metastasis and reduced overall survival [71–73]. These findings align with research linking UCHL1 overexpression to tumor progression, increased size, and invasiveness [74]. Therefore, understanding the molecular alterations associated with UCHL1 hypomethylation-induced upregulation, targeted therapies can be developed to modulate UCHL1 expression, offering a potential avenue for therapeutic intervention in Ov-CCA.

Loss of Tumor Suppressors p14ARF, p15INK4b, p16INK4a

Separate genes encode p14ARF (p14 Alternate Reading Frame), p15INK4b (p15 Inhibitor of Kinase 4B), and p16INK4a (p16 Inhibitor of Kinase 4A), yet are closely related and functionally connected. CDKN2A encodes p16INK4A and p14ARF, CDKN2B encodes p15INK4B [75]. CDKN2A and CDKN2B have been associated with poorer prognosis in meningioma, acute lymphoblastic leukemia and lung adenocarcinoma [76–78].

Liver fluke CCA cases exhibited notable elevated occurrences of promoter hypermethylation in the p14 (40.2%), p15 (48.9%), and p16 (28.3%) genes [19]. In Ov-CCA, it is characterised by frequent LOH at the chromosomal region 9p21-other, which affects these key tumor suppressor genes p14ARF, p15INK4b, and p16INK4a [19]. The presence of senescence markers like p14ARF allows the elimination of aberrant aneuploid cells through apoptosis [79]. Still, in Ov-CCA, p14ARF is often lost, which may diminish the apoptotic response, allowing the uncontrolled proliferation of abnormal cells and potentially facilitating cancer progression [80].

The methylation of the p16INK4a promoter primarily arises from DNA damage resulting from interference between transcription and replication processes [81]. Therefore, the CDKN2A/B methylation and expression changes show promise as prognostic biomarkers and therapeutic targets related to DNA damage and repair mechanisms in Ov-CCA.

Potential Roles of Hypermethylated DCR1, HIC1, SFRP1 and PTEN in Ov-CCA Development

High-frequency methylation of CpG island promoters is a prominent mechanism in intrahepatic CCA (iCCA) [82], influencing various cancer types and contributing to tumor initiation and progression through genome-wide and gene-specific DNA methylation alterations [83]. In Ov-CCA, promoter hypermethylation in several CpG islands genes, such as (DcR1, SFRP1, PTEN, H1C1, and DcR1) exhibited a methylation frequency exceeding 28% compared to adjacent normal tissue [8].

Decoy receptor (DcRs) often downregulated through promoter hypermethylation in cancer, overexpression reduces sensitivity to TNF-related apoptosis-inducing ligand (TRAIL) -induced apoptosis and DNA-damaging agents. At the same time, its silencing enhances chemotherapeutic agent-induced apoptosis, indicating its significant role in chemosensitivity regulation [84,85]. In Ov-CCA, patients exhibiting methylation at the DcR1 locus displayed a greater survival rate than those without methylation [8,86], indicating the potential use of recombinant TRAIL and TRAIL receptor agonists for Ov-CCA treatment. This observation may also be attributed to the role of DcR1 as a decoy, impeding TRAIL binding to death receptors and suppressing the apoptotic process, as observed in tongue carcinoma [87].

The methylation of the promoter region of the secreted frizzled-related protein 1 (SFRP1) holds potential as a diagnostic indicator and therapeutic target, particularly in specific malignancies like ampullary adenocarcinoma and gastric cancer, where its upregulation is linked to poor prognoses [88,89]. In a survey study involving 73 patients diagnosed with primary Ov-CCA, the median methylation levels for SFRP1 were 31.5% [90]. The analysis indicated that SFRP1 exhibited a sensitivity of 83.56%, a specificity of 100%, and an overall accuracy of 85.54%. As a secreted protein, detecting SFRP1 methylation in blood or other biofluids could enable non-invasive screening and monitoring of Ov-CCA.

The tumor suppressor PTEN loss is common in many cancers, including CCA [91]. PTEN loss in the Ov-CCA hamster model shows extensive alterations in DNA methylation and gene expression, ultimately activating the PI3K/AKT/PTEN and Wnt/β-catenin pathways, pivotal in governing cellular growth, proliferation, survival, and metabolism [92]. PTEN helps counteract the activity of PI3K, which is often hyperactivated in opisthorchiasis-induced CCA and promotes cell survival, proliferation, and growth [93]. Hence, hyperactivation of this pathway due to PTEN inactivation may enhance cancer progression during opisthorchiasis.

HIC1 (Hypermethylated in Cancer 1), a tumor suppresser gene, triggered G2/M cell cycle arrest in a glioblastoma cell line model, potentially through induction of full-length p53 and its downstream cell cycle regulators p21 and p27 [94]. In contrast, the truncated p53 isoform Δ133p53 was associated with 5-fluorouracil chemoresistance in Ov-CCA models, and its inhibition restored drug sensitivity CCA [95]. Given HIC1’s role as a transcriptional repressor that interacts with p53, these findings suggest epigenetic silencing of HIC1 may promote chemoresistance in Ov-CCA by altering p53 regulation and cell cycle control. Therefore, targeting the HIC1-p53 axis therapeutically, through approaches like demethylating agents or Δ133p53 inhibitors, may help enhance response to chemotherapy in Ov-CCA patients.

Histone Modification as a Biomarker and Therapeutic Target in Ov-CCA

The “writer” of H3K27me3, Enhancer of zest homolog 2 (EZH2), has been known to be involved in tumor progression and is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that targets lysine-27 of histone H3 [96,97]. Mice exhibiting liver specific EZH2 knockout demonstrated reduced CCA development, while also, in a xenograft model, EZH2 knockdown markedly slowed the progression of CCA [98]. Similarly, in Ov-CCA tissue samples, high EZH2 expression is associated with poorer survival, and combined high EZH2, SUZ12, and EED correlated with a worse prognosis [99].

The unique upregulation of H3K27me3 by the PRC2 complex in Ov-CCA, notably involving EZH2 and SUZ12 compared to other cancers, signifies a specific epigenetic mechanism contributing to its aggressiveness, potentially making histone-modifying enzymes like EZH2 viable targets for treatment and prognosis evaluation [99]. Dysregulation of the PRC2–H3K27me3 axis is linked to different diseases, including several cancers [96,100] and inflammatory processes [101]. Therefore, SUZ12 and EED are other essential components of the PRC2 complex. SUZ12 stabilises PRC2 and is necessary for its methyltransferase activity [102], and EED interacts with EZH2 and helps guide PRC2 [103] to its target sites on chromatin [104]. Recently, compounds that disrupt the interaction between EZH2 and EED have been developed, leading to the destabilisation and degradation of PRC2 proteins, which could provide a new avenue for cancer therapy [104,105]. These compounds represent a range of strategies for targeting components of the PRC2 complex, offering potential therapeutic avenues for various cancers, including CCA and Ov-CCA.

In summary, both DNA methylation and histone epigenetic alterations appear as crucial events in Ov-CCA (Fig 2). However, it’s important to note that regulating the genes and proteins is complex and context-dependent. The specific pathways and mechanisms involved in their upregulation or downregulation may vary in different cell types and under other conditions. Understanding these regulatory mechanisms is essential for developing targeted therapies and diagnostic approaches for diseases involving their dysregulation.

10.1371/journal.pntd.0012477.g002 Fig 2 Genes and Proteins involved in epigenetic regulation of Ov-CCA (Created with BioRender.com).

3.2.2 Gene Set Enrichment Analysis of Epigenes in Ov-CCA

The genes identified in this review, implicated in Ov-CCA pathology, underwent Enrichment analysis using Enrichr (https://maayanlab.cloud/Enrichr/) against the Wiki Pathway Collection library [106], an open-access platform supported by a collaborative scientific community. In total 23 genes (hMLH1, RIZ1, Trop2, ERBB2, EBF1, OPCML, HOXA9, HOXD9, HTATIP2, UCHL1, p14ARF, p15INK4b, p16INK4a, EZH2, SUZ12, H3K27, PTEN, H1C1, PRC2, DKK1, DCR1, HIC1, SFRP1) identified in Ov-CCA epigenetic alterations were subjected to gene set enrichment analysis (Fig 3A). The top five predicted pathways based on highest combined score were selected and shown in a bar chart (Fig 3B).

10.1371/journal.pntd.0012477.g003 Fig 3 (A) Ov-CCA-associated genes (B) Top five predicted pathways for genes involved in Ov-CCA. This analysis revealed pathways exhibiting the greatest overlap with the queried gene set. Notably, Wnt signalling appeared twice in the chart with the highest combined score. A higher combined score indicated lower p-values (greater statistical significance) and increased gene overlap, reinforcing the enrichment confidence. These research findings also merit researchers investigating genes and pathways in pleural mesothelioma.

3.2.3 Identifying Hub Genes and Pathway Dysregulation in Ov-CCA

To be more species specific, the STRING database [107] was used to predict protein-protein interactions involving these genes (Fig 3A), which includes both physical interactions and functional associations. These genes were analyzed with the most deregulated pathways related to Ov-CCA. These pathways were compiled from literature reviews and underwent manual screening of titles and abstracts, using specific keywords. The most deregulated pathways based on Ov-CCA studies were PI3K (Phosphoinositide 3-kinase), AKT (protein kinase B), mTOR (mammalian target of rapamycin), PTEN (phosphatase and tensin homolog), CTNNB1 (Catenin Beta-1), NAKB1 (Nuclear Factor Kappa B Subunit 1), MAPK (Mitogen-Activated Protein Kinase), and RTK (Receptor Tyrosine Kinase).

In the STRING database, hub genes exhibit extensive connectivity within a network, underscoring their pivotal role and significant impact on biological processes through interactions with multiple partners. β-catenin (CTNNB1) demonstrated elevated centrality values relative to other ranked genes in the network, suggesting its potential as a target for pathway-specific therapies or drug interventions in Ov-CCA (Fig 4B). CTNNB1 showed the highest score at 47670 (Fig 4C). A higher score suggests the gene likely acts as a central hub in biological networks, facilitating interactions across various pathways and processes.

10.1371/journal.pntd.0012477.g004 Fig 4 (A) STRING interaction of genes and pathways involved in Ov-CCA. (B)Top 7 genes showed in Hierichial layout. (C) Ranked gene names and string interaction scores.

3.2.4 Wnt/β-catenin signalling pathway emerges as a common signalling pathway in Ov-CCA

The Wnt pathway utilises canonical (Wnt/β-catenin) and noncanonical (Wnt/Ca2+ and planar cell polarity) routes. The canonical pathway involves β-catenin activation of genes through TCF/LEF. and noncanonical pathways regulate cell polarity and migration independently of β-catenin-TCF/LEF, forming a distinct network from the canonical pathway’s control over cell proliferation. [108].

Wnt ligands play a pivotal role by interacting with cell membrane-bound receptors and co-receptors, influencing critical physiological and pathophysiological functions across various organs and cell types. These functions include organ development, cancer formation, and fibrosis [109]. In molecular oncology research, comprehending the underlying mechanisms of the anti-tumor effects and pathways involved in overall CCA progression is pivotal for tailoring targeted therapies, ensuring treatment efficacy, and reducing adverse effects [110,111]. Our analysis showed that Wnt/β signalling predominantly emerges in Ov-CCA (Table 2).

Most of the discussed genes/proteins appear to function by suppressing Wnt/β-catenin signalling in Ov-CCA. In Ov-CCA research, although hMLH1 isn’t directly linked to the Wnt signalling pathway, the hypermethylation of the DNA mismatch repair (MMR) gene MLH1’s promoter and microsatellite instability (MSI)-related tumors have been correlated with WNT signalling activation, likely through frameshift insertion/deletion mutations [112]. This activation can result in reduced tumor-infiltrating lymphocytes (TILs) and resistance to immune checkpoint inhibitor (ICI) therapy [113,114], suggesting a less favourable environment for the immune system to mount an effective anti-cancer response. The loss of hMLH1 in Ov-CCA is mainly associated with DNA repair [115], and deviant methylation patterns within DNA damage repair genes hold the potential to function as predictive, prognostic, and chemosensitive markers in the context of human cancer [116].

In human tissue samples of Ov-CCA, RIZ1 gene methylation and epigenetic alteration were associated with poorer survival [17,51]. RIZ1 suppresses Wnt signalling via β-catenin in breast cancer and parathyroid tumors [117,118], implying a conserved negative regulatory role of RIZ1 in the β-catenin pathway across these malignancies. Therefore, targeting Wnt signalling and restoring RIZ1 function shows potential in overall CCA treatment. However, contextual factors like age, gender, and organ may influence RIZ1’s function, as in estrogen-related cancer, as it exhibits a dual role, acting as both a promoter and inhibitor of tumor growth, highlighting its complex and context-dependent nature [119].

In Ov-CCA, Trop2 is frequently hypermethylated, causing growth and metastatic advantages to the biliary cancer cells [16], which sets them apart from other cancer types. Trop2 co-localizes with β-catenin in the nucleus, upregulating cyclin D1 and c-myc, fostering nuclear oncogene transcription and cell proliferation [120]. The Wnt-β-catenin signalling pathway can modulate the activation of β-catenin, a pivotal element in Wnt signalling, thereby indirectly influencing the Wnt signalling cascade [121]. Therefore, the unique hypermethylation of Trop2 in Ov-CCA cells implies that it does not play its usual role in interacting with the Wnt/β-catenin pathway to affect cancer progression but rather a suppressive effect fostering tumorigenesis in O. viverrini infection.

EBF1 is frequently hypermethylated and silenced epigenetically in its promoter region in Ov-CCA tissues [18]. EBF1 is linked to regulating genes associated with the immune response and cytokine production, including IL-6 [122]. Furthermore, the IL-6/STAT3 signalling pathway is implicated in the hypermethylation of the EBF1 promoter, demonstrating that IL-6 potentially plays a role in this epigenetic modification [123]. IL-6 also can interact with Wnt signalling pathways, aiding in repair and regeneration [124]. Both IL-1β and IL-6 are widely produced in O. viverrini infection [125,126], and these interleukins have significantly reduced Dickkopf-1 (DKK1) production using Wnt signalling pathway, potentially causing an abnormal Wnt pathway [127]. Additionally, in bioinformatics analyses of gene expression data sets in intrahepatic (iCCA) and extrahepatic (eCCA) cholangiocarcinomas, DKK1 was identified alongside MMP7 as a distinguishing marker between these cancer types [128].

Aberrant Wnt activation drives abnormal cell growth and neoplastic transformation, while concurrent CDKN2A/B deficiency synergistically promotes tumorigenesis via Wnt signalling pathway activation [129]. This combined effect substantially increases the risk of cancer, highlighting the pivotal roles of both elements in suppressing tumors. In Ov-CCA, aberrant p14ARF methylation, resulting from DNA damage, reduces its expression, impacting genomic stability. CDKN2A and TP53 are crucial, with p14ARF from CDKN2A enhancing p53’s tumor-suppressing functions [130]. Additionally, the loss of the CDKN2A/B locus, which encodes essential cell cycle inhibitors like p16INK4A and p15INK4B, is common in Ov-CCA. This loss may cause the co-deletion of the tumor suppressor gene methylthioadenosine phosphorylase (MTAP), resulting in uncontrolled cell proliferation [131], as MTAP is located on the 9p21 chromosome, where CDKN2A/B is also located.CDKN2A/B and MTAP loss, p16INK4A methylation, senescence marker downregulation, and p53 alteration reflect fundamental genomic and epigenetic changes in Ov-CCA pathogenesis.

EZH2 silences Wnt pathway antagonists, activating Wnt/β-catenin signalling in hepatocellular carcinomas, contributing to their proliferation and suggesting a potential therapeutic target [132]. EZH2 transactivates genes commonly targeted by estrogen and Wnt signalling pathways [133]. In the context of anaplastic thyroid carcinoma (ATC), the inhibition of EZH2 has been demonstrated to suppress Wnt/β-catenin signalling, thereby contributing to its oncogenic role, with targeting EZH2 resulting in reduced β-catenin activity and consequential effects on proliferation and invasion [134]. However, in the context of Ov-CCA, EZH2 is overexpressed, potentially disrupting balanced Wnt/β-catenin signalling and resulting in heightened β-catenin downstream signalling. Similarly, in cervical cancer, the overexpression of EZH2 promotes tumor progression by enhancing cell proliferation and tumor formation through activation of the Wnt/β-catenin pathway, achieved via epigenetic silencing of GSK-3β and TP53 [135]. In chemoresistant Head and Neck Squamous Cell Carcinoma (HNSCC) cells, both the Wnt/β-catenin pathway and EZH2 are upregulated, indicating a relationship between higher EZH2 expression and Wnt/β-catenin pathway activation, contributing to chemoresistance and cancer stem cell accumulation [136].

SFRP1, in O. viverrini infection, is known to serve as a Wnt inhibitor and is overexpressed in EZH2-deficient tissues [137]. Wnt proteins initiate intracellular signalling pathways by binding to frizzled (FZ) receptors and coreceptors, thus revealing their cellular effects [138], and notably, in the case of Ov-CCA, it has been observed that SFRP1 is downregulated from hypermethylation, supporting the finding of EZH2 overexpression leading to decreased SFRP1. The upregulation of EZH2 and downregulation of SFRP1 in the context of O. viverrini infection may play a crucial role in aberrant expression of the Wnt/β-catenin pathway, and it may also be associated with the activation of Wnt/β-catenin signalling and the consequential proliferation of CCA cells. Regulating this mechanism can potentially control cell proliferation, migration, and invasion in opisthorchiasis while maintaining an effective immune response that supports the survival of the host-parasite relationship. These findings underscore the epigenetic significance of SFRP1 and EZH2 unique to Ov-CCA and suggest potential avenues for therapeutic intervention.

In Ov-CCA, the highest methylation frequency of OPCML was observed (72.5%), indicating its potential use as an epigenetic biomarker for CCA prognosis and diagnosis. In the context of esophageal cancer, OPCML’s downregulation in Grade 3 tumors may implicate its regulatory role in the Wnt/β-catenin signalling pathway, potentially contributing to the development and progression of higher-grade tumors [139]. This relationship remains unexplored in Ov-CCA tissue samples and cases. OPCML, also a stress- and p53-responsive gene, when hypermethylated, diminishes the response; introducing OPCML in carcinoma cells lacking it results in substantial growth inhibition, highlighting its potential as a tumor suppressor [140]. A Mutant p53 (mutp53) protein can interact with components of the Wnt pathway, such as β-catenin, to enhance their activity.

Generally, TP53 mutations activate the Wnt pathway via mutp53 interaction [141], fostering poorly differentiated and invasive tumors in cancer. Without TP53’s normal tumor suppressor function, mutp53 can influence other pathways, including Wnt, that drive cancer progression [142]. Missense TP53 mutations directly affect the Wnt pathway, and in O. viverrini infection, exon 6 TP53 mutations may contribute to cholangiocarcinogenesis [143]. Hence, elevating components of the Wnt pathway through the attenuation of p53 signalling has been demonstrated to be a critical factor in promoting the formation of metastases [144]. Crosstalk between the p53 and Wnt pathways involves direct interactions, where p53 can regulate the stability and subcellular location of β-catenin. Additionally, these pathways affect each other’s protein stability and gene expression, influencing essential cancer-related genes [142].

Cancer research actively investigates potential treatment drugs to modulate the Wnt/β-catenin signalling pathway, a key player in cancer progression. These drugs can either inhibit or activate Wnt signalling, depending on the specific disease type, stage, and lesion characteristics, as highlighted by recent studies [145,146]. Further exploration is needed to determine whether targeting epigenetically activated genes and proteins could potentially suppress Ov-CCA tumors by regulating the Wnt pathway and whether the epigenetic status of these genes and proteins could serve as a useful biomarker in this context.

4. Wnt/β-catenin as a therapeutic target for Ov-CCA

Extensive research has uncovered genetic alterations in cancer-related signalling pathways, leading to the development of targeted therapies [147]. Using String-DB [148], network analysis revealed a notable interaction pattern among the 23 dysregulated epigenes, notably with β-catenin and Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) ranking second highest in the analysis (Fig 4).

Wnt/β-catenin signalling, known for directly or indirectly suppressing various Cyclin-Dependent Kinase Inhibitor proteins (CKIs, or CDKNs). For example, p16, encoded by p16INK4A (CDKN2A), is an inhibitor of CDK4, and the expressions of cyclin D1 and CDK4 are up-regulated in opisthorchiasis-associated CCA [149]. There is a possibility that the expression of β-catenin may prevent senescence by suppressing p16INK4A expression [150]. Therefore, the downregulation of p16INK4A may allow cancer cells to bypass senescence and continue proliferating, contributing to tumor progression. Furthermore, the Wnt target, MYC, inhibits the transcription of several other CKIs, including CDKN1A (p21), CDKN1B (p27), and CDKN2B (p15) [151], all of which demonstrate hypermethylation Ov-CCA and CCA.

Various strategies to inhibit this pathway are being explored in preclinical and clinical studies, including blocking porcupine enzymes, silencing DKK1, targeting microRNAs, and regulating the PI3K/AKT/PTEN/GSK-3β, retinoic acid receptor (RAR), protein kinase A regulatory subunit 1 alpha (PRKAR1A/PKAI), liver kinase B1 (LKB1) and CXCR4 axes that modulate β-catenin activity and its downstream target genes [152,153]. Therefore, investigating whether the dysregulation mentioned above is a shared feature among different causative agents of Ov-CCA would provide valuable insights for the potential use of Wnt/β-catenin targeted therapies in the overall management of CCA.

Dickkopf-1 (DKK1), a soluble antagonist of the Wnt/β-catenin signalling pathway, is elevated in the serum of patients with various cancers and animal models of chronic inflammatory diseases [154]. The bidirectional relationships between DKK1 and inflammation, influenced by systemic inflammatory signals and local tumor inflammation, highlight its intricate involvement in disease pathways [155]. Considering its association with immunosuppressive phenotypes in iCCA [156], DKK1 emerges as a potential therapeutic target for iCCA [157]. In O. viverrini infection, IL-6 and IL-1β are upregulated [158], and both of these interleukins may significantly dampen Wnt antagonist Dickkopf-1 (DKK1) [127,159]. The activation of Wnt signalling via downregulation of DKK1 may impact downstream pathways, such as NF-κB, which govern inflammatory responses [160] during O. viverrini infection. Therefore, exploring DKK1’s role in Ov-CCA and its impact on NF-κB and Wnt/β-catenin crosstalk is crucial for identifying potential anti-cancer therapy targets.

The suppression of PRKAR1A expression resulted in growth inhibition and apoptosis of Ov-CCA, while its overexpression was correlated with elevated levels of ECPKA autoantibodies [161]. ECPKA shows potential as a cancer biomarker, with the prospect of being utilised to differentiate between malignant tumors and benign conditions [162]. Furthermore, silencing PRKAR1A reduces multiple signalling pathways and can affect various intracellular signalling pathways, including MAPKs, PI3K/Akt, JAK/STAT, and Wnt/β-catenin, influencing CCA cell behaviour and growth [163]. These discoveries highlight the potential of targeting the PKA pathway to regulate Wnt/β-catenin in Ov-CCA therapy, alone or in combination with other anticancer drugs.

CXCR4, a chemokine receptor, is involved in downstream signalling triggered by the interaction of CD63 with N-glycans found on tetraspanin (TSPs) released by O. viverrini [164]. Elevated CXCR4 expression has been linked to iCCA progression and metastases [165], and CXCR4 knockdown has been correlated with the suppression of Wnt target genes and the inhibition of malignant biliary tract tumor progression [165,166]. A better understanding of how O. viverrini infection influences CXCR4 expression and associated signalling cascades may provide key insights into and strategies to suppress CXCR4-driven Wnt activation and disease progression in Ov-CCA patients.

Extensive research has uncovered genetic alterations in cancer-related signalling pathways, leading to the development of targeted therapies [147]. Dysfunctional Wnt/β-catenin signalling is a crucial pathway in numerous cancers and diseases, impacting cell proliferation, invasion, and stemness and leading to enduring epigenetic alterations in gene expression [108,167]. Our review study identified all epigenetic-based studies on opisthorchiasis-induced CCA, the types of epigenetic modifications involved, and their potential as biomarkers and therapeutic applications (Table 2). Through this analysis, we observed that the Wnt/β-catenin signal transduction pathway is frequently dysregulated in Ov-CCA, primarily due to promoter methylation. Given that the Wnt/β-catenin pathway has emerged as a central player in CCA, its alteration is associated with worse outcomes in specific CCA subtypes [152]. Hence, exploring the complex Wnt signalling pathway offers promising and innovative therapeutic opportunities for treating Ov-CCA, as well as non-Ov-CCA. Although clinical trials testing Wnt pathway inhibitors have been undertaken, they have not yet received approval. The primary obstacle lies in the remarkable evolutionary conservation of the canonical WNT/β-catenin signalling pathway, a pivotal regulator of tissue development and homeostasis [168]. Nevertheless, some trials combining Wnt inhibition with chemotherapeutic drugs have shown promise [169].

5. Discussion and conclusion

In the post-genomic era, the epigenetic foundation of cancer development has brought about a significant transformation in cancer genetics. This breakthrough has introduced new avenues for therapeutic interventions in cancer treatment [170]. This scoping review investigates the genes associated with epigenetic changes in the progression of liver fluke-induced cancer, examining their interplay with Wnt- β-catenin signalling in Ov-CCA. The study provides valuable insights into potential biomarkers and therapeutic targets related to epigenetic studies in O. viverrini infection. The Wnt/β-catenin signalling pathway offers a promising target for opisthorchiasis-induced cancer therapy, given its central role in cancer progression and its potential as a focus for inhibitors. The analysis also elucidates strategies leveraging epigenetic markers for therapeutic interventions. While its involvement in carcinogenesis is well-characterized, aberrant Wnt signalling is also observed in various other cancer types.

Wnt/β-catenin signalling is central to cancer research for its key role in cancer development and progression. In this paper, we systematically examined studies investigating the epigenetic mechanisms underlying Ov-CCA (Fig 5). All clinical samples in our study were obtained from patients diagnosed with Ov-CCA and were analyzed across selected studies. The predominant epigenetic alterations involved DNA hypermethylation of promoter CpG islands, notably impacting the expression of tumor suppressor genes. Numerous genes displayed hypermethylation in Ov-CCA tissues compared to normal tissues, including hMLH1, RIZ1, Trop2, EBF1, p14ARF, p15INK4b, p16INK4a, OPCML, PTEN, and SFRP1. Gene set enrichment analysis revealed the Wnt/β-catenin pathway as the most significantly enriched pathway associated with these differentially methylated genes. Moreover, network analysis identified β-catenin as a central hub gene interacting with multiple epigenetically altered genes. Collectively, these findings suggest dysfunctional Wnt/β-catenin signalling as a common pathological mechanism in Ov-CCA, primarily driven by aberrant promoter hypermethylation. Since the Wnt pathway regulates critical processes like proliferation, pathogenesis, invasion, and stemness, targeting this pathway may offer therapeutic benefits for Ov-CCA. However, medications targeting Wnt/β-catenin signalling in cancers are either not yet in clinical trials or are in early-phase trials with unsatisfactory outcomes [171]. In conclusion, this scoping review enhances understanding of the epigenetic landscape in Ov-CCA and provides insights towards developing novel targeted and precision therapies for this disease.

10.1371/journal.pntd.0012477.g005 Fig 5 This review is the first to scope, collate, and catalogue research investigating epigenetic markers for diagnosis and therapeutic potential in Ov-CCA.

It identifies several potentially valuable epigenetic markers and potential drug targets, encouraging further exploration. Additionally, it sheds light on shared signalling pathways that could help design future studies focused on epigenetics in this field. The findings of this research present promising avenues for developing epigenetic-based therapeutic strategies and differential biomarkers in the treatment of Ov-CCA. (Created with BioRender.com).

In recent years, there has been an increase in the incidence of CCA, yet its prognosis remains challenging [172]. This is primarily due to its limited surgical resection success rate and its resistance to traditional radiotherapy and chemotherapy methods, which pose significant challenges for effective treatment [173]. Unlike genetic mutations, epigenetic alterations are reversible and dynamically influenced by the tumour microenvironment, making them attractive candidates for minimally invasive testing and disease progression tracking. Hence, understanding the underlying mechanisms driving CCA pathogenesis induced during O. viverrini infection, the factors governing its growth, signalling pathways, and leveraging epigenetics offer a promising avenue for personalised, targeted therapies and enhanced diagnostic and prognostic capacities in disease management. Ultimately, this study intends to offer guidance for future research by identifying key considerations and insights essential for developing more targeted therapies for Wnt/β-catenin signalling in cancer.

6. Limitations

Extensive research has elucidated that canonical and non-canonical Wnt signalling impacts cancer by interacting with the microenvironment and immune system, with non-canonical signalling regulating cell motility in both development and metastasis, while their balance varies across different tissues and tumours [174]. Moreover, variability in laboratory procedures across different studies could have contributed to variations in test results, and it’s important to note that the analysis was primarily performed on samples from the primary tumour, potentially introducing intra-tumour heterogeneity, as the papers did not specify whether patients were being treated for their metastases. Furthermore, this review did not examine small non-coding RNAs like microRNAs and long noncoding RNAs (lncRNAs). These can serve as multifactorial epigenetic gene regulators by modifying transcription and post-transcriptional regulation and signalling pathways. The absence of research addressing these aspects in Ov-CCA and epigenetic markers is a notable limitation within both the scope of Ov-CCA studies and this specific scoping review. Further future research should focus on distinguishing Ov-CCA-specific methylation changes from those influenced by non-Ov-CCA factors using comprehensive techniques like methylated DNA immunoprecipitation microarray (MeDIP-chip) genome-wide analysis. This can help identify definitive diagnostic epigenetic markers for CCA and advance our understanding of this disease. The absence of precise numerical data while studying epigenetic alteration reported in O. viverrini lacks in-depth statistical analysis, including sensitivity, specificity, AUC, OR, RR, and survival rates, within the included study text precludes a comprehensive assessment of the biomarker efficacy of epigenetic markers or their therapeutic prospects.

Supporting information

S1 Table The PCC (Population/Concept/Context) framework employed to structure key concepts, focusing on the crucial involvement of DNA methylation and histone modifications in Ov-CCA pathogenesis.

(DOCX)

S2 Table The core methodologies frequently applied in Ov-CCA methylation studies.

(DOCX)

10.1371/journal.pntd.0012477.r001
Decision Letter 0
Taylan Ozkan Aysegul Academic Editor
Bradbury Richard Stewart Section Editor
© 2024 Taylan Ozkan, Bradbury
2024
Taylan Ozkan, Bradbury
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
3 Jun 2024

Dear Dr. Suttiprapa,

Thank you very much for submitting your manuscript "Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Aysegul Taylan Ozkan, M.D., Ph.D.,

Academic Editor

PLOS Neglected Tropical Diseases

Richard Bradbury

Section Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: This review meet the above method conditions.

Reviewer #3: Yes

Yes

Yes

Yes

Yes

Yes

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: Yes.

Reviewer #3: Yes

Yes

Yes

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: Yes

Reviewer #3: Yes

Yes

Yes

Yes

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: accept

Reviewer #3: Review comment

This review article is well organized and is appropriate to the objective.

However, there are some points to be questioned, as follows:

1. In Section “3. Results”, page 9.

“The initial search yielded 495 records from the four electronic databases.”

In Figure 1. Flowchart depicting the identification and selection process of studies, page 10.

“Records identified through database search (n=1050)”

The number “495 records” and “n = 1050”, which number is an initial searching record?

2. In Section “3.1 Sample Size and Techniques”, page 10

“immunohistochemistry (IHC), quantitative PCR (qPCR), and comprehensive computational analysis (supplementary 2)”

Is supplementary 2 refer to Supplementary Table 2?

3. In “TP53 Mutations and EBB2 Amplification in Ov-CCA”, page 15

Is EBB2 the same gene as (ERBB2) described in the text?

4. In Section “5. Conclusion and perspectives:”, page 31

The authors have mentioned that “Unlike genetic mutations, epigenetic alterations are reversible and dynamically influenced by the tumour microenvironment, making them attractive candidates for minimally invasive testing and disease progression tracking.”

How does tumor microenvironment influence epigenetic alterations? Or what evidence that support this tumor microenvironment related epigenetic changes?

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The authors conducted a systematic analysis of the available papers on the methylation state of individual genes in human samples from patients suffered from Opisthorchis viverrini-associated cholangiocarcinoma. The study was conducted to identify individual target genes for the subsequent development of gene therapy. The materials and methods are presented in clear and straightforward style. Nevertheless, I have suggestions for the Results section that would improve the manuscript since it requires major revision.

1. The lack of line numbering is unhelpful for the reviewer

2. In my opinion, the manuscript does not have enough examples of differences in hypermethylation of regulatory regions of individual genes compared to that in other types of cancer. I recommend indicating whether this is a characteristic feature of Ov-associated CCA or not. At the same time, the authors still provide such information about individual genes (Trop2 and RIZ1), but not for all genes. If there is no such information, then I recommend mentioning that there is no information.

3. The study also lacks a table that would summarize the most important findings for the characterization of Ov-associated CCA, in particular a table with examples of specific hypermethylated regions of genes unique to Ov-CCA would be useful.

4. It is necessary to write all genes and all proteins in accordance with the nomenclature rules for writing human genes (please refer to HUGO Gene Nomenclature Committee (HGNC)

5. This review is not sufficiently illustrated. In my opinion, the manuscript lacks clear gene networks or crosstalks between signaling pathways to illustrate the main findings.

Minor

1. page 29, 3rd paragraph – unreadable characters,

2. the Reference list is written in a different style and font

3. p.27, mutp53 should be decrypted the first time it appears in the text

Reviewer #2: This review identified epigenetic changes and Wnt/β-catenin pathway deregulation as key drivers in Ov-CCA pathogenesis. This study underscores the importance of the epigenetic modifications in Ov-CCA development, suggesting novel therapeutic targets within disrupted signaling networks. It is very interesting and valuable for therapy of Ov-CCA.

Reviewer #3: (No Response)

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

10.1371/journal.pntd.0012477.r002
Author response to Decision Letter 0
Submission Version1
31 Jul 2024

Attachment Submitted filename: Response to the reviewers_PNTD-D-24-00341_R1.docx

10.1371/journal.pntd.0012477.r003
Decision Letter 1
Taylan Ozkan Aysegul Academic Editor
Bradbury Richard Stewart Section Editor
© 2024 Taylan Ozkan, Bradbury
2024
Taylan Ozkan, Bradbury
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
19 Aug 2024

Dear Dr. Suttiprapa,

We are pleased to inform you that your manuscript 'Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Aysegul Taylan Ozkan, M.D., Ph.D.,

Academic Editor

PLOS Neglected Tropical Diseases

Richard Bradbury

Section Editor

PLOS Neglected Tropical Diseases

***********************************************************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #3: (No Response)

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #3: The authors have clearly explained all comments/questions. This manuscript has enough scientific merit to be published in the journal.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

10.1371/journal.pntd.0012477.r004
Acceptance letter
Taylan Ozkan Aysegul Academic Editor
Bradbury Richard Stewart Section Editor
© 2024 Taylan Ozkan, Bradbury
2024
Taylan Ozkan, Bradbury
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
1 Sep 2024

Dear Dr. Suttiprapa,

We are delighted to inform you that your manuscript, "Epigenetic Biomarkers and the Wnt/β-Catenin Pathway in Opisthorchis viverrini-associated Cholangiocarcinoma: A Scoping Review on Therapeutic Opportunities," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases
==== Refs
References

1 Saijuntha W , Sithithaworn P , Petney TN , Andrews RH . Foodborne zoonotic parasites of the family Opisthorchiidae. Research in Veterinary Science. 2021;135 :404–11. doi: 10.1016/j.rvsc.2020.10.024 33158552
2 Sripa B , Kaewkes S , Sithithaworn P , Mairiang E , Laha T , Smout M , et al . Liver fluke induces cholangiocarcinoma. PLoS Med. 2007;4 (7 ):e201. doi: 10.1371/journal.pmed.0040201 17622191
3 Cancer IAfRo. Schistosomes, liver flukes and Helicobacter pylori: IARC Lyon; 1994.
4 Sithithaworn P , Andrews RH , Nguyen VD , Wongsaroj T , Sinuon M , Odermatt P , et al . The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol Int. 2012;61 (1 ):10–6. doi: 10.1016/j.parint.2011.08.014 21893213
5 Sripa B , Pairojkul C . Cholangiocarcinoma: lessons from Thailand. Current opinion in gastroenterology. 2008;24 (3 ):349. doi: 10.1097/MOG.0b013e3282fbf9b3 18408464
6 Mairiang E , Haswell-Elkins MR , Mairiang P , Sithithaworn P , Elkins DB . Reversal of biliary tract abnormalities associated with Opisthorchis viverrini infection following praziquantel treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1993;87 (2 ):194–7. doi: 10.1016/0035-9203(93)90489-d 8337727
7 Jusakul A , Kongpetch S , Teh BT . Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Curr Opin Gastroenterol. 2015;31 (3 ):258–63. doi: 10.1097/MOG.0000000000000162 25693006
8 Sriraksa R , Zeller C , El-Bahrawy MA , Dai W , Daduang J , Jearanaikoon P , et al . CpG-island methylation study of liver fluke-related cholangiocarcinoma. British Journal of Cancer. 2011;104 (8 ):1313–8. doi: 10.1038/bjc.2011.102 21448164
9 Chan-On W , Nairismägi ML , Ong CK , Lim WK , Dima S , Pairojkul C , et al . Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45 (12 ):1474–8. doi: 10.1038/ng.2806 24185513
10 Limpaiboon T. Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pac J Cancer Prev. 2012;13 (Suppl ):41–5. 23480763
11 Zhang H , Yang T , Wu M , Shen F . Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379 (2 ):198–205. doi: 10.1016/j.canlet.2015.09.008 26409434
12 Neganova ME , Klochkov SG , Aleksandrova YR , Aliev G . Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology. 2022;83 :452–71. doi: 10.1016/j.semcancer.2020.07.015 32814115
13 Li Y , Fan Z , Meng Y , Liu S , Zhan H . Blood-based DNA methylation signatures in cancer: A systematic review. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease. 2023;1869 (1 ):166583. doi: 10.1016/j.bbadis.2022.166583 36270476
14 Lianidou E . Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook. Mol Oncol. 2021;15 (6 ):1683–700. doi: 10.1002/1878-0261.12978 33942482
15 Limpaiboon T , Khaenam P , Chinnasri P , Soonklang M , Jearanaikoon P , Sripa B , et al . Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett. 2005;217 (2 ):213–9. doi: 10.1016/j.canlet.2004.06.020 15617839
16 Sawanyawisuth K , Tantapotinan N , Wongkham C , Riggins GJ , Kraiklang R , Wongkham S , et al . Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol. 2016;15 (1 ):71–81. doi: 10.5604/16652681.1184223 26626643
17 Khaenam P , Jearanaikoon P , Pairojkul C , Bhudhisawasdi V , Limpaiboon T . Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma. Exp Ther Med. 2010;1 (2 ):385–90. doi: 10.3892/etm_00000060 22993552
18 Armartmuntree N , Jusakul A , Sakonsinsiri C , Loilome W , Pinlaor S , Ungarreevittaya P , et al . Promoter hypermethylation of early B cell factor 1 (EBF1) is associated with cholangiocarcinoma progression. J Cancer. 2021;12 (9 ):2673–86. doi: 10.7150/jca.52378 33854627
19 Chinnasri P , Pairojkul C , Jearanaikoon P , Sripa B , Bhudhisawasdi V , Tantimavanich S , et al . Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Hum Pathol. 2009;40 (6 ):817–26. doi: 10.1016/j.humpath.2008.11.002 19200577
20 Nanok C , Jearanaikoon P , Proungvitaya S , Limpaiboon T . Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma. Mol Med Rep. 2018;17 (3 ):4145–53. doi: 10.3892/mmr.2017.8319 29359783
21 Wasenang W , Chaiyarit P , Proungvitaya S , Limpaiboon T . Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clinical Epigenetics. 2019;11 (1 ):39. doi: 10.1186/s13148-019-0634-0 30832707
22 Pećina-Šlaus N , Kafka A , Salamon I , Bukovac A . Mismatch Repair Pathway, Genome Stability and Cancer. Front Mol Biosci. 2020;7 :122. doi: 10.3389/fmolb.2020.00122 32671096
23 Boland CR , Thibodeau SN , Hamilton SR , Sidransky D , Eshleman JR , Burt RW , et al . A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58 (22 ):5248–57. 9823339
24 Deng G , Peng E , Gum J , Terdiman J , Sleisenger M , Kim YS . Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer. 2002;86 (4 ):574–9. doi: 10.1038/sj.bjc.6600148 11870540
25 Levine AJ , Phipps AI , Baron JA , Buchanan DD , Ahnen DJ , Cohen SA , et al . Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors. Cancer Epidemiol Biomarkers Prev. 2016;25 (1 ):68–75. doi: 10.1158/1055-9965.EPI-15-0935 26512054
26 Kim JH , Rhee YY , Bae JM , Kwon HJ , Cho NY , Kim MJ , et al . Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status. Mod Pathol. 2013;26 (7 ):1013–22. doi: 10.1038/modpathol.2012.241 23370766
27 Thomas DC , Umar A , Kunkel TA . Microsatellite instability and mismatch repair defects in cancer. Mutat Res. 1996;350 (1 ):201–5. doi: 10.1016/0027-5107(95)00112-3 8657182
28 Khuntikeo N , Padthaisong S , Loilome W , Klanrit P , Ratchatapusit S , Techasen A , et al . Mismatch Repair Deficiency Is a Prognostic Factor Predicting Good Survival of Opisthorchis viverrini-Associated Cholangiocarcinoma at Early Cancer Stage. 2023;15 (19 ):4831.
29 Parente P , Grillo F , Vanoli A , Macciomei MC , Ambrosio MR , Scibetta N , et al . The Day-To-Day Practice of MMR and MSI Assessment in Colorectal Adenocarcinoma: What We Know and What We Still Need to Explore. Dig Dis. 2023;41 (5 ):746–56. doi: 10.1159/000531003 37231848
30 Lipinski M , Parks DR , Rouse RV , Herzenberg LA . Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci U S A. 1981;78 (8 ):5147–50. doi: 10.1073/pnas.78.8.5147 7029529
31 Shvartsur A , Bonavida B . Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes & cancer. 2015;6 (3–4 ):84–105. doi: 10.18632/genesandcancer.40 26000093
32 Liu X , Deng J , Yuan Y , Chen W , Sun W , Wang Y , et al . Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacology & Therapeutics. 2022;239 :108296. doi: 10.1016/j.pharmthera.2022.108296 36208791
33 Vaskivuo TE , Stenbäck F , Tapanainen JS . Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer. 2002;95 (7 ):1463–71. doi: 10.1002/cncr.10876 12237915
34 Boonmars T , Srisawangwong T , Srirach P , Kaewsamut B , Pinlaor S , Sithithaworn P . Apoptosis-related gene expressions in hamsters re-infected with Opisthorchis viverrini and re-treated with praziquantel. Parasitology research. 2007;102 (1 ):57–62. doi: 10.1007/s00436-007-0724-3 17851691
35 Wang X , Lin Y , Lan F , Yu Y , Ouyang X , Liu W , et al . BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Medical Oncology. 2014;31 :1–10. doi: 10.1007/s12032-014-0249-4 25267570
36 Liu Z , Ding Y , Ye N , Wild C , Chen H , Zhou J . Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev. 2016;36 (2 ):313–41. doi: 10.1002/med.21379 26395559
37 Seubwai W , Wongkham C , Puapairoj A , Khuntikeo N , Pugkhem A , Hahnvajanawong C , et al . Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy. PLoS One. 2014;9 (8 ):e106056.25170898
38 Bentires-Alj M , Dejardin E , Viatour P , Van Lint C , Froesch B , Reed JC , et al . Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines. Oncogene. 2001;20 (22 ):2805–13.11420692
39 Zhao M , DiPeri TP , Raso MG , Zheng X , Rizvi YQ , Evans KW , et al . Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. npj Breast Cancer. 2023;9 (1 ):66. doi: 10.1038/s41523-023-00573-8 37567892
40 Zhang C , Zhu Q , He H , Jiang L , Qiang Q , Hu L , et al . RIZ1: a potential tumor suppressor in glioma. BMC Cancer. 2015;15 (1 ):990. doi: 10.1186/s12885-015-2023-1 26690953
41 Xue Y , Chen R , Du W , Yang F , Wei X . RIZ1 and histone methylation status in pituitary adenomas. Tumor Biology. 2017;39 (7 ):1010428317711794. doi: 10.1177/1010428317711794 28718376
42 Romualdo GR , Heidor R , Bacil GP , Moreno FS , Barbisan LF . Past, present, and future of chemically induced hepatocarcinogenesis rodent models: Perspectives concerning classic and new cancer hallmarks. Life Sciences. 2023;330 :121994. doi: 10.1016/j.lfs.2023.121994 37543357
43 Steele-Perkins G , Fang W , Yang X-H , Van Gele M , Carling T , Gu J , et al . Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein–methyltransferase superfamily. Genes & development. 2001;15 (17 ):2250–62. doi: 10.1101/gad.870101 11544182
44 Saha Roy S , Vadlamudi RK . Role of Estrogen Receptor Signaling in Breast Cancer Metastasis. International Journal of Breast Cancer. 2012;2012 :654698. doi: 10.1155/2012/654698 22295247
45 Mann M , Cortez V , Vadlamudi RK . Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy. Cancers. 2011;3 (2 ):1691–707. doi: 10.3390/cancers3021691 21814622
46 Yang T , Ren C , Jiang A , Yu Z , Li G , Wang G , et al . RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer. Biochemical and Biophysical Research Communications. 2017;489 (2 ):96–102. doi: 10.1016/j.bbrc.2017.05.095 28528974
47 Di Zazzo E , Porcile C , Bartollino S , Moncharmont B . Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors. Biology. 2016;5 (4 ). doi: 10.3390/biology5040054 27983647
48 Takeshita T , Tokumaru Y , Oshi M , Wu R , Patel A , Tian W , et al . Clinical relevance of estrogen reactivity in the breast cancer microenvironment. Frontiers in oncology. 2022;12 :865024. doi: 10.3389/fonc.2022.865024 35677163
49 Kozieł MJ , Piastowska-Ciesielska AW . Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer. Int J Mol Sci. 2023;24 (19 ). doi: 10.3390/ijms241914673 37834120
50 Hunsawong T , Singsuksawat E , In-chon N , Chawengrattanachot W , Thuwajit C , Sripa B , et al . Estrogen is increased in male cholangiocarcinoma patients’ serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. Journal of Cancer Research and Clinical Oncology. 2012;138 (8 ):1311–20. doi: 10.1007/s00432-012-1207-1 22476540
51 Khaenam P , Niibori A , Okada S , Jearanaikoon P , Araki N , Limpaiboon T . Contribution of RIZ1 to regulation of proliferation and migration of a liver fluke-related cholangiocarcinoma cell. Asian Pac J Cancer Prev. 2012;13 (8 ):4007–11. doi: 10.7314/apjcp.2012.13.8.4007 23098508
52 Neve RM , Chin K , Fridlyand J , Yeh J , Baehner FL , Fevr T , et al . A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer cell. 2006;10 (6 ):515–27. doi: 10.1016/j.ccr.2006.10.008 17157791
53 Mullighan CG , Goorha S , Radtke I , Miller CB , Coustan-Smith E , Dalton JD , et al . Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446 (7137 ):758–64. doi: 10.1038/nature05690 17344859
54 Shen A , Chen Y , Liu L , Huang Y , Chen H , Qi F , et al . EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway. Cancer Res. 2019;79 (9 ):2257–70. doi: 10.1158/0008-5472.CAN-18-3238 30862720
55 Xing M , Ooi WF , Tan J , Qamra A , Lee PH , Li Z , et al . Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. J Clin Invest. 2020;130 (6 ):3005–20. doi: 10.1172/JCI126726 32364535
56 Armartmuntree N , Murata M , Techasen A , Yongvanit P , Loilome W , Namwat N , et al . Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis. Redox biology. 2018;14 :637–44. doi: 10.1016/j.redox.2017.11.011 29169115
57 Mesuraca M , Chiarella E , Scicchitano S , Codispoti B , Giordano M , Nappo G , et al . ZNF423 and ZNF521: EBF1 Antagonists of Potential Relevance in B-Lymphoid Malignancies. BioMed research international. 2015;2015 :165238. doi: 10.1155/2015/165238 26788497
58 Chaiprasert T , Armartmuntree N , Techasen A , Sakonsinsiri C , Pinlaor S , Ungarreevittaya P , et al . Roles of Zinc Finger Protein 423 in Proliferation and Invasion of Cholangiocarcinoma through Oxidative Stress. Biomolecules. 2019;9 (7 ):263. doi: 10.3390/biom9070263 31284679
59 Lotesto M , Raimondi S . EBF1 Exhibits Crosstalk Regulation with ERα and ERβ in Some Hormone-Based Cancers. OBM Genetics. 2020;04 (04 ):117.
60 Mantovani F , Collavin L , Del Sal G . Mutant p53 as a guardian of the cancer cell. Cell death and differentiation. 2019;26 (2 ):199–212. doi: 10.1038/s41418-018-0246-9 30538286
61 Kiba T , Tsuda H , Pairojkul C , Inoue S , Sugimura T , Hirohashi S . Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog. 1993;8 (4 ):312–8. doi: 10.1002/mc.2940080415 8280380
62 Puetkasichonpasutha J , Namwat N , Sa-Ngiamwibool P , Titapun A , Suthiphongchai T . Evaluation of p53 and Its Target Gene Expression as Potential Biomarkers of Cholangiocarcinoma in Thai Patients. Asian Pacific journal of cancer prevention: APJCP. 2020;21 (3 ):791–8. doi: 10.31557/APJCP.2020.21.3.791 32212809
63 Jusakul A , Cutcutache I , Yong CH , Lim JQ , Huang MN , Padmanabhan N , et al . Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discov. 2017;7 (10 ):1116–35. doi: 10.1158/2159-8290.CD-17-0368 28667006
64 Titapun A , Techasen A , Sa-Ngiamwibool P , Sithithaworn P , Luvira V , Srisuk T , et al . Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression. International journal of general medicine. 2020;13 :1271–83. doi: 10.2147/IJGM.S282519 33273846
65 Wynn CS , Tang SC . Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer metastasis reviews. 2022;41 (1 ):193–209. doi: 10.1007/s10555-022-10021-x 35142964
66 Sriraksa R , Zeller C , Dai W , Siddiq A , Walley AJ , Limpaiboon T , et al . Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. Cancer Prev Res (Phila). 2013;6 (12 ):1348–55. doi: 10.1158/1940-6207.CAPR-13-0104 24089088
67 Ye F , Zhang S-F , Xie X , Lu W-G . OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma. Cancer investigation. 2008;26 (6 ):569–74. doi: 10.1080/07357900701837044 18584347
68 Khamko R , Daduang J , Settasatian C , Limpaiboon T . OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation. Cancer genomics & proteomics. 2021;18 (6 ):771–80. doi: 10.21873/cgp.20296 34697068
69 Bouras E , Karakioulaki M , Bougioukas KI , Aivaliotis M , Tzimagiorgis G , Chourdakis M . Gene promoter methylation and cancer: An umbrella review. Gene. 2019;710 :333–40. doi: 10.1016/j.gene.2019.06.023 31202904
70 Razin A , Cedar H . DNA methylation and gene expression. Microbiol Rev. 1991;55 (3 ):451–8. doi: 10.1128/mr.55.3.451-458.1991 1943996
71 Lee YM , Lee JY , Kim MJ , Bae HI , Park JY , Kim SG , et al . Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci. 2006;97 (11 ):1205–10. doi: 10.1111/j.1349-7006.2006.00320.x 16965602
72 Mondal M , Conole D , Nautiyal J , Tate EW . UCHL1 as a novel target in breast cancer: emerging insights from cell and chemical biology. British Journal of Cancer. 2022;126 (1 ):24–33. doi: 10.1038/s41416-021-01516-5 34497382
73 Schröder C , Milde-Langosch K , Gebauer F , Schmid K , Mueller V , Wirtz RM , et al . Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. Journal of cancer research and clinical oncology. 2013;139 :1745–55. doi: 10.1007/s00432-013-1496-z 23996067
74 Yamazaki T , Hibi K , Takase T , Tezel E , Nakayama H , Kasai Y , et al . PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002;8 (1 ):192–5. 11801558
75 Krimpenfort P , Ijpenberg A , Song JY , van der Valk M , Nawijn M , Zevenhoven J , et al . p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature. 2007;448 (7156 ):943–6. doi: 10.1038/nature06084 17713536
76 Perry A , Banerjee R , Lohse CM , Kleinschmidt-DeMasters BK , Scheithauer BW . A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol. 2002;12 (2 ):183–90. doi: 10.1111/j.1750-3639.2002.tb00433.x 11958372
77 Peng Y , Chen Y , Song M , Zhang X , Li P , Yu X , et al . Co-occurrence of CDKN2A/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Mol Oncol. 2022;16 (8 ):1746–60. doi: 10.1002/1878-0261.13206 35253368
78 Ruan Y , Xie L , Zou A . Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children. Journal of Cancer Research and Clinical Oncology. 2023;149 (12 ):10841–50. doi: 10.1007/s00432-023-04974-x 37314514
79 Safwan-Zaiter H , Wagner N , Wagner KD . P16INK4A-More Than a Senescence Marker. Life (Basel). 2022;12 (9 ). doi: 10.3390/life12091332 36143369
80 Cilluffo D , Barra V , Di Leonardo A . P14(ARF): The Absence that Makes the Difference. Genes (Basel). 2020;11 (7 ). doi: 10.3390/genes11070824 32698529
81 Tramontano A , Boffo FL , Russo G , De Rosa M , Iodice I , Pezone A . Methylation of the Suppressor Gene p16INK4a: Mechanism and Consequences. Biomolecules. 2020;10 (3 ):446. doi: 10.3390/biom10030446 32183138
82 Lee S , Kim WH , Jung HY , Yang MH , Kang GH . Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol. 2002;161 (3 ):1015–22. doi: 10.1016/S0002-9440(10)64262-9 12213730
83 Geiman TM , Muegge K . DNA methylation in early development. Mol Reprod Dev. 2010;77 (2 ):105–13. doi: 10.1002/mrd.21118 19921744
84 Liu X , Yue P , Khuri FR , Sun SY . Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 2005;65 (20 ):9169–75. doi: 10.1158/0008-5472.CAN-05-0939 16230375
85 Shivapurkar N , Toyooka S , Toyooka KO , Reddy J , Miyajima K , Suzuki M , et al . Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer. 2004;109 (5 ):786–92. doi: 10.1002/ijc.20041 14999791
86 Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer. 2006;94 (2 ):179–83. doi: 10.1038/sj.bjc.6602918 16404435
87 Zhou Y , Zheng S , Luo Q , Huang X , Zhou Y , Li Z . Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma. American Journal of Otolaryngology. 2019;40 (6 ):102258. doi: 10.1016/j.amjoto.2019.07.002 31399243
88 Baharudin R , Tieng FYF , Lee LH , Ab Mutalib NS . Epigenetics of SFRP1: The Dual Roles in Human Cancers. Cancers (Basel). 2020;12 (2 ). doi: 10.3390/cancers12020445 32074995
89 Cheng L-C , Chao Y-J , Overman MJ , Wang CY , Phan NN , Chen Y-L , et al . Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Scientific Reports. 2020;10 (1 ):13255. doi: 10.1038/s41598-020-69899-8 32764696
90 Amornpisutt R , Proungvitaya S , Jearanaikoon P , Limpaiboon T . DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumor Biology. 2015;36 (7 ):4973–8. doi: 10.1007/s13277-015-3147-2 25652468
91 Wang C , Feng Y , Zhang C , Cheng D , Wu R , Yang Y , et al . PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer. Faseb j. 2020;34 (1 ):1304–18. doi: 10.1096/fj.201901205RR 31914691
92 Yothaisong S , Thanee M , Namwat N , Yongvanit P , Boonmars T , Puapairoj A , et al . Opisthorchis viverrini infection activates the PI3K/ AKT/PTEN and Wnt/β-catenin signaling pathways in a Cholangiocarcinogenesis model. Asian Pac J Cancer Prev. 2014;15 (23 ):10463–8.25556493
93 Prasopdee S , Yingchutrakul Y , Roytrakul S , Pholhelm M , Phanaksri T , Kunjantarachot A , et al . Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta as a potential biomarker for Opisthorchis viverrini infection and cholangiocarcinoma. Parasitology. 2022;149 (2 ):171–80. doi: 10.1017/S0031182021001694 35234600
94 Kumar S. P53 induction accompanying G2/M arrest upon knockdown of tumor suppressor HIC1 in U87MG glioma cells. Mol Cell Biochem. 2014;395 (1–2 ):281–90. doi: 10.1007/s11010-014-2137-9 24992983
95 Nutthasirikul N , Hahnvajanawong C , Techasen A , Limpaiboon T , Leelayuwat C , Chau-In S , et al . Targeting the Δ133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. Int J Oncol. 2015;47 (6 ):2153–64.26459801
96 Kim KH , Roberts CW . Targeting EZH2 in cancer. Nat Med. 2016;22 (2 ):128–34. doi: 10.1038/nm.4036 26845405
97 Simon JA , Lange CA . Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutation research. 2008;647 (1–2 ):21–9. doi: 10.1016/j.mrfmmm.2008.07.010 18723033
98 Zhang J , Chen W , Ma W , Han C , Song K , Kwon H , et al . EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes. Am J Pathol. 2022;192 (12 ):1712–24. doi: 10.1016/j.ajpath.2022.08.008 36456043
99 Wasenang W , Puapairoj A , Settasatian C , Proungvitaya S , Limpaiboon T . Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma. Pathology—Research and Practice. 2019;215 (7 ):152451. doi: 10.1016/j.prp.2019.152451 31126817
100 Bracken AP , Pasini D , Capra M , Prosperini E , Colli E , Helin K . EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo j. 2003;22 (20 ):5323–35. doi: 10.1093/emboj/cdg542 14532106
101 Stazi G , Taglieri L , Nicolai A , Romanelli A , Fioravanti R , Morrone S , et al . Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype. Clin Epigenetics. 2019;11 (1 ):173. doi: 10.1186/s13148-019-0763-5 31791385
102 Højfeldt JW , Laugesen A , Willumsen BM , Damhofer H , Hedehus L , Tvardovskiy A , et al . Accurate H3K27 methylation can be established de novo by SUZ12-directed PRC2. Nature structural & molecular biology. 2018;25 (3 ):225–32. doi: 10.1038/s41594-018-0036-6 29483650
103 Cao Q , Wang X , Zhao M , Yang R , Malik R , Qiao Y , et al . The central role of EED in the orchestration of polycomb group complexes. Nat Commun. 2014;5 :3127. doi: 10.1038/ncomms4127 24457600
104 Tomassi S , Romanelli A , Zwergel C , Valente S , Mai A . Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders. J Med Chem. 2021;64 (16 ):11774–97. doi: 10.1021/acs.jmedchem.1c00226 34351144
105 Wan G , Feng H , Su C , Zhu Y , Zhang L , Zhang Q , et al . A patent review of EZH2 inhibitors from 2017 and beyond. Expert Opinion on Therapeutic Patents. 2023;33 (4 ):293–308. doi: 10.1080/13543776.2023.2206018 37095742
106 Agrawal A , Balcı H , Hanspers K , Coort SL , Martens M , Slenter DN , et al . WikiPathways 2024: next generation pathway database. Nucleic acids research. 2024;52 (D1 ):D679–D89. doi: 10.1093/nar/gkad960 37941138
107 Szklarczyk D , Gable AL , Nastou KC , Lyon D , Kirsch R , Pyysalo S , et al . The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Research. 2020;49 (D1 ):D605–D12.
108 Liu J , Xiao Q , Xiao J , Niu C , Li Y , Zhang X , et al . Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy. 2022;7 (1 ):3.34980884
109 Schinner S , Willenberg HS , Schott M , Scherbaum WA . Pathophysiological aspects of Wnt-signaling in endocrine disease. Eur J Endocrinol. 2009;160 (5 ):731–7. doi: 10.1530/EJE-08-0831 19246555
110 Wen N , Guo B , Zheng H , Xu L , Liang H , Wang Q , et al . Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway. Int J Oncol. 2019;55 (4 ):879–95. doi: 10.3892/ijo.2019.4863 31485609
111 Li B , Li A , You Z , Xu J , Zhu S . Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma. Cell Death & Disease. 2020;11 (10 ):823. doi: 10.1038/s41419-020-03031-6 33009370
112 Savio AJ . The Dynamic Interplay of Epigenetics and Genetics in Selected DNA Mismatch Repair and Wnt Signaling Pathway Genes in Colorectal Cancer: University of Toronto (Canada); 2017.
113 Guan J , Li G-M . DNA mismatch repair in cancer immunotherapy. NAR Cancer. 2023;5 (3 ). doi: 10.1093/narcan/zcad031 37325548
114 Irina T , Valentina S , Valeriu T , Victor S , Jean CA , Mariela V-S , et al . #103 Epigenetic silencing of MLH1 as a prognostic factor for endometrial cancer recurrence. 2023;33 (Suppl 3 ):A131–A2.
115 Martínez-Marcial LA , Jacinto-Alemán LF , Trejo-Remigio DA , Ramírez-Martínez CM , Leyva-Huerta ERJO-IJoDS . Methylation analysis of Rb, P16, MGMT, and hMLH-1in mucoepidermoid carcinomas. A pilot study. 2023;25 (2 ):123–32.
116 Gao D , Herman JG , Guo M . The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget. 2016;7 (24 ):37331–46. doi: 10.18632/oncotarget.7949 26967246
117 Liang Q , Li W , Zhao Z , Fu Q . Advancement of Wnt signal pathway and the target of breast cancer. Open Life Sciences. 2016;11 (1 ):98–104.
118 Starker LF , Svedlund J , Udelsman R , Dralle H , Akerström G , Westin G , et al . The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer. 2011;50 (9 ):735–45. doi: 10.1002/gcc.20895 21638518
119 Lipovka Y , Konhilas JP . The complex nature of oestrogen signalling in breast cancer: enemy or ally? Biosci Rep. 2016;36 (3 ). doi: 10.1042/BSR20160017 27160081
120 Stoyanova T , Goldstein AS , Cai H , Drake JM , Huang J , Witte ON . Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev. 2012;26 (20 ):2271–85.23070813
121 Toumi M , Mathe I . Trop2: A Key Player in Oncology-From Research to Clinical Application. J Gene Engg Bio Res. 2023;5 (2 ):124–32.
122 Griffin MJ , Zhou Y , Kang S , Zhang X , Mikkelsen TS , Rosen ED . Early B-cell factor-1 (EBF1) is a key regulator of metabolic and inflammatory signaling pathways in mature adipocytes. The Journal of biological chemistry. 2013;288 (50 ):35925–39. doi: 10.1074/jbc.M113.491936 24174531
123 Isomoto H , Mott JL , Kobayashi S , Werneburg NW , Bronk SF , Haan S , et al . Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. 2007;132 (1 ):384–96. doi: 10.1053/j.gastro.2006.10.037 17241887
124 Purwaningrum M , Giachelli CM , Osathanon T , Rattanapuchpong S , Sawangmake C . Dissecting specific Wnt components governing osteogenic differentiation potential by human periodontal ligament stem cells through interleukin-6. Scientific Reports. 2023;13 (1 ):9055. doi: 10.1038/s41598-023-35569-8 37270571
125 Sripa B , Thinkhamrop B , Mairiang E , Laha T , Kaewkes S , Sithithaworn P , et al . Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS neglected tropical diseases. 2012;6 (5 ):e1654. doi: 10.1371/journal.pntd.0001654 22629477
126 Promthet S , Songserm N , Woradet S , Pientong C , Ekalaksananan T , Wiangnon S , et al . Opisthorchiasis with proinflammatory cytokines (IL-1β and TNF-α) polymorphisms influence risk of intrahepatic cholangiocarcinoma in Thailand: a nested case-control study. BMC Cancer. 2018;18 (1 ):846.30139338
127 Yoshida Y , Yamasaki S , Oi K , Kuranobu T , Nojima T , Miyaki S , et al . IL-1β Enhances Wnt Signal by Inhibiting DKK1. Inflammation. 2018;41 (5 ):1945–54.29956067
128 Kutlu A , Arda M , Atak E , Ulukaya EJIJoMB . Identification of key genes and pathways for cholangiocarcinoma using an integrated bioinformatics analysis. 2022;5 (3 ).
129 Krimpenfort P , Snoek M , Lambooij J-P , Song J-Y , van der Weide R , Bhaskaran R , et al . A natural WNT signaling variant potently synergizes with Cdkn2ab loss in skin carcinogenesis. Nature Communications. 2019;10 (1 ):1425. doi: 10.1038/s41467-019-09321-8 30926782
130 Schulz WA . Tumor Suppressor Genes. In: Schulz WA , editor. Molecular Biology of Human Cancers. Cham: Springer International Publishing; 2023. p. 97–120.
131 Illei PB , Rusch VW , Zakowski MF , Ladanyi M . Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clinical Cancer Research. 2003;9 (6 ):2108–13. 12796375
132 Cheng AS , Lau SS , Chen Y , Kondo Y , Li MS , Feng H , et al . EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011;71 (11 ):4028–39.21512140
133 Shi B , Liang J , Yang X , Wang Y , Zhao Y , Wu H , et al . Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol. 2007;27 (14 ):5105–19. doi: 10.1128/MCB.00162-07 17502350
134 de Mello DC , Saito KC , Cristovão MM , Kimura ET , Fuziwara CS . Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer. International Journal of Molecular Sciences. 2023;24 (9 ):7872. doi: 10.3390/ijms24097872 37175580
135 Chen Q , Zheng PS , Yang WT . EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma. Oncotarget. 2016;7 (24 ):36115–29.27092879
136 Milan TM , Eskenazi APE , Oliveira LD , Silva GD , Bighetti-Trevisan RL , Freitas GP , et al . Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets. Cellular signalling. 2023;109 :110773.37331417
137 Liu L , Xiao B , Hirukawa A , Smith HW , Zuo D , Sanguin-Gendreau V , et al . Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways. Proceedings of the National Academy of Sciences. 2023;120 (33 ):e2303010120. doi: 10.1073/pnas.2303010120 37549258
138 Hösch NG , Martins BB , Alcantara QA , Bufalo MC , Neto BS , Chudzinki-Tavassi AM , et al . Wnt signaling is involved in crotalphine-induced analgesia in a rat model of neuropathic pain. European Journal of Pharmacology. 2023;959 :176058. doi: 10.1016/j.ejphar.2023.176058 37739305
139 Singh V , Singh AP , Sharma I , Singh LC , Sharma J , Borthakar BB , et al . Epigenetic deregulations of Wnt/β-catenin and transforming growth factor beta-Smad pathways in esophageal cancer: Outcome of DNA methylation. J Cancer Res Ther. 2019;15 (1 ):192–203.30880778
140 Cui Y , Ying Y , van Hasselt A , Ng KM , Yu J , Zhang Q , et al . OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PloS one. 2008;3 (8 ):e2990. doi: 10.1371/journal.pone.0002990 18714356
141 Prowald A , Cronauer MV , von Klot C , Eilers T , Rinnab L , Herrmann T , et al . Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. The Prostate. 2007;67 (16 ):1751–60. doi: 10.1002/pros.20660 17929268
142 Xiao Q , Werner J , Venkatachalam N , Boonekamp KE , Ebert MP , Zhan T . Cross-Talk between p53 and Wnt Signaling in Cancer. Biomolecules. 2022;12 (3 ). doi: 10.3390/biom12030453 35327645
143 Tangkawattana S , Kaewkes S , Pairojkul C , Tangkawattana P , Sripa B . Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model. Asian Pacific journal of cancer prevention: APJCP. 2008;9 (1 ):101–6. 18439086
144 Powell E , Piwnica-Worms D , Piwnica-Worms H . Contribution of p53 to metastasis. Cancer discovery. 2014;4 (4 ):405–14. doi: 10.1158/2159-8290.CD-13-0136 24658082
145 Zhang X , Li C , Wu Y , Cui P . The research progress of Wnt/β-catenin signaling pathway in colorectal cancer. Clinics and Research in Hepatology and Gastroenterology. 2023;47 (3 ):102086.36657523
146 Hiremath IS , Goel A , Warrier S , Kumar AP , Sethi G , Garg M . The multidimensional role of the Wnt/β-catenin signaling pathway in human malignancies. Journal of cellular physiology. 2022;237 (1 ):199–238.34431086
147 Liu F , Wang L , Perna F , Nimer SD . Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape. Nature Reviews Cancer. 2016;16 (6 ):359–72. doi: 10.1038/nrc.2016.41 27220480
148 Szklarczyk D , Kirsch R , Koutrouli M , Nastou K , Mehryary F , Hachilif R , et al . The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Research. 2022;51 (D1 ):D638–D46.
149 Boonmars T , Wu Z , Boonjaruspinyo S , Pinlaor S , Nagano I , Takahashi Y , et al . Alterations of gene expression of RB pathway in Opisthorchis viverrini infection-induced cholangiocarcinoma. Parasitology research. 2009;105 (5 ):1273–81. doi: 10.1007/s00436-009-1548-0 19582476
150 Delmas V , Beermann F , Martinozzi S , Carreira S , Ackermann J , Kumasaka M , et al . β-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. 2007;21 (22 ):2923–35.
151 Bretones G , Delgado MD , León J . Myc and cell cycle control. Biochimica et biophysica acta. 2015;1849 (5 ):506–16. doi: 10.1016/j.bbagrm.2014.03.013 24704206
152 Lozano E , Sanchon-Sanchez P , Morente-Carrasco A , Chinchilla-Tábora LM , Mauriz JL , Fernández-Palanca P , et al . Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity. Cells. 2023;12 (8 ).
153 Zhang GF , Qiu L , Yang SL , Wu JC , Liu TJ . Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma. Bioscience reports. 2020;40 (3 ).
154 Mazon M , Larouche V , St-Louis M , Schindler D , Carreau M . Elevated blood levels of Dickkopf-1 are associated with acute infections. Immun Inflamm Dis. 2018;6 (4 ):428–34. doi: 10.1002/iid3.232 30028084
155 Park MH , Shin JH , Bothwell ALM , Chae WJ . Dickkopf proteins in pathological inflammatory diseases. J Leukoc Biol. 2022;111 (4 ):893–901. doi: 10.1002/JLB.3RI0721-385R 34890067
156 Jarman EJ , Horcas-Lopez M , Waddell SH , MacMaster S , Gournopanos K , Soong DYH , et al . DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01. Liver Int. 2023;43 (1 ):208–20. doi: 10.1111/liv.15383 35924447
157 Shi RY , Yang XR , Shen QJ , Yang LX , Xu Y , Qiu SJ , et al . High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013;119 (5 ):993–1003. doi: 10.1002/cncr.27788 23132676
158 Surapaitoon A , Suttiprapa S , Khuntikeo N , Pairojkul C , Sripa B . Cytokine profiles in Opisthorchis viverrini stimulated peripheral blood mononuclear cells from cholangiocarcinoma patients. Parasitol Int. 2017;66 (1 ):889–92. doi: 10.1016/j.parint.2016.10.009 27769807
159 Li X , Wang J , Zhu S , Zheng J , Xie Y , Jiang H , et al . DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma. Blood Advances. 2021;5 (18 ):3656–67.34470047
160 Ma B , Hottiger MO . Crosstalk between Wnt/β-Catenin and NF-κB Signaling Pathway during Inflammation. Front Immunol. 2016;7 :378.27713747
161 Loilome W , Yooyuen S , Namwat N , Sithithaworn P , Puapairoj A , Kano J , et al . PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2012;33 (6 ):2289–98. doi: 10.1007/s13277-012-0491-3 22922884
162 Lee J-E , Song W-J , Lee H , Kim B-G , Kim T , Lee C , et al . AniScan Using Extracellular Cyclic AMP-Dependent Protein Kinase A as a Serum Biomarker Assay for the Diagnosis of Malignant Tumors in Dogs. 2020;20 (15 ):4075.
163 Loilome W , Juntana S , Namwat N , Bhudhisawasdi V , Puapairoj A , Sripa B , et al . PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer. 2011;129 (1 ):34–44. doi: 10.1002/ijc.25646 20824711
164 Ruangsuwast A , Smout MJ , Brindley PJ , Loukas A , Laha T , Chaiyadet S . Tetraspanins from Opisthorchis viverrini stimulate cholangiocyte migration and inflammatory cytokine production. bioRxiv: the preprint server for biology. 2023.
165 Zhao S , Wang J , Qin CJJoE , Research CC . Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. 2014;33 (1 ):1–12. doi: 10.1186/s13046-014-0103-8 25471741
166 Zhao S , Wang J , Qin C . Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. Journal of experimental & clinical cancer research: CR. 2014;33 (1 ):103. doi: 10.1186/s13046-014-0103-8 25471741
167 Nusse R , Clevers H . Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169 (6 ):985–99.28575679
168 Xu Y , Liu J , Tian Y , Wang Z , Song Z , Li K , et al . Wnt/β-Catenin Signaling Pathway Is Strongly Implicated in Cadmium-Induced Developmental Neurotoxicity and Neuroinflammation: Clues from Zebrafish Neurobehavior and In Vivo Neuroimaging. International journal of molecular sciences. 2022;23 (19 ).
169 Kahn M. Can we safely target the WNT pathway? Nature reviews Drug discovery. 2014;13 (7 ):513–32. doi: 10.1038/nrd4233 24981364
170 Miranda Furtado CL , Dos Santos Luciano MC , Silva Santos RD , Furtado GP , Moraes MO , Pessoa C . Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14 (12 ):1164–76. doi: 10.1080/15592294.2019.1640546 31282279
171 Yu F , Yu C , Li F , Zuo Y , Wang Y , Yao L , et al . Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduction and Targeted Therapy. 2021;6 (1 ):307.34456337
172 O’Hagan K. Updates in Cholangiocarcinoma. J Adv Pract Oncol. 2022;13 (3 ):320–3. doi: 10.6004/jadpro.2022.13.3.28 35663158
173 Wang N , Huang A , Kuang B , Xiao Y , Xiao Y , Ma H . Progress in Radiotherapy for Cholangiocarcinoma. Front Oncol. 2022;12 :868034. doi: 10.3389/fonc.2022.868034 35515132
174 Zhan T , Rindtorff N , Boutros M . Wnt signaling in cancer. Oncogene. 2017;36 (11 ):1461–73. doi: 10.1038/onc.2016.304 27617575
175 Liu Q , Qu X , Xie X , He P , Huang S . Repression of Akt3 gene transcription by the tumor suppressor RIZ1. Scientific Reports. 2018;8 (1 ):1528. doi: 10.1038/s41598-018-19943-5 29367689
176 Xiaolei X , Peixin J , Jinghong Z , Junjian M , Kefan W , Kangyi Z . A review of RIZ1 regulation of the signal pathways in obesity and tumors. Journal of Shanghai Jiaotong University (Medical Science). 2023;43 (1 ).
177 Qiu Z , Guo W , Dong B , Wang Y , Deng P , Wang C , et al . EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1α pathway. Proceedings of the National Academy of Sciences. 2022;119 (28 ):e2119518119.
178 Györy I , Boller S , Nechanitzky R , Mandel E , Pott S , Liu E , et al . Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. Genes & development. 2012;26 (7 ):668–82. doi: 10.1101/gad.187328.112 22431510
179 Araos J , Sleeman JP , Garvalov BKJC , metastasis e. The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. 2018;35 (7 ):563–99.
180 Bheda A , Yue W , Gullapalli A , Whitehurst C , Liu R , Pagano JS , et al . Positive reciprocal regulation of ubiquitin C-terminal hydrolase L1 and beta-catenin/TCF signaling. PLoS One. 2009;4 (6 ):e5955. doi: 10.1371/journal.pone.0005955 19536331
181 Mandelker DL , Yamashita K , Tokumaru Y , Mimori K , Howard DL , Tanaka Y , et al . PGP9. 5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer research. 2005;65 (11 ):4963–8. doi: 10.1158/0008-5472.CAN-04-3923 15930319
182 Shenoy US , Adiga D , Kabekkodu SP , Hunter KD , Radhakrishnan R . Molecular implications of HOX genes targeting multiple signaling pathways in cancer. Cell Biology and Toxicology. 2022;38 (1 ):1–30. doi: 10.1007/s10565-021-09657-2 34617205
183 Zhong B , Liao Q , Wang X , Wang X , Zhang J . The roles of epigenetic regulation in cholangiocarcinogenesis. Biomedicine & Pharmacotherapy. 2023;166 :115290. doi: 10.1016/j.biopha.2023.115290 37557012
184 Ricuphan K , Wiphawan W , Jureerut D , Chatri S , Temduang L . Combined OPCML and AXL Expression as a Prognostic Marker and OPCML Enhances AXL Inhibitor in Cholangiocarcinoma. In Vivo. 2022;36 (3 ):1168. doi: 10.21873/invivo.12816 35478117
185 Ishikawa S , Ito K . Plasticity and regulatory mechanisms of Hox gene expression in mouse neural crest cells. Cell and tissue research. 2009;337 (3 ):381–91. doi: 10.1007/s00441-009-0827-5 19585150
186 Rapani E , Sacchetti A , Corda D , Alberti SJIjoc . Human Trop-2 is a tumor-associated calcium signal transducer. 1998;76 (5 ):671–6. doi: 10.1002/(sici)1097-0215(19980529)76:5&lt;671::aid-ijc10&gt;3.0.co;2-7 9610724
187 Cubas R , Zhang S , Li M , Chen C , Yao Q . Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9 :253. doi: 10.1186/1476-4598-9-253 20858281
